

THE HEALTH PROFESSIONAL'S GUIDE TO

Nutrition Management of Thyroid Disease

NICOLE ANZIANI, MS, RD, CDN, CDCES

With Introduction and Medical Review by
FRANCESCO CELI, MD, MHSC

Academy of Nutrition and Dietetics
120 S. Riverside Plaza, Suite 2190
Chicago, IL 60606

The Health Professional's Guide to Nutrition Management of Thyroid Disease

978-0-88091-019-4 (print)
978-0-88091-022-4 (eBook)
Catalog Number 019420 (print)
Catalog Number 019420e (eBook)

Copyright © 2020, Academy of Nutrition and Dietetics. All rights reserved. Except for brief quotations embodied in critical articles or reviews, no part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written consent of the publisher.

The views expressed in this publication are those of the authors and do not necessarily reflect policies and/or official positions of the Academy of Nutrition and Dietetics. Mention of product names in this publication does not constitute endorsement by the authors or the Academy of Nutrition and Dietetics. The Academy of Nutrition and Dietetics disclaims responsibility for the application of the information contained herein.

10 9 8 7 6 5 4 3 2 1

For more information on the Academy of Nutrition and Dietetics, visit www.eatright.org.

Library of Congress Cataloging-in-Publication Data

Names: Anziani, Nicole, author.

Title: The health professional's guide to nutrition management of thyroid disease / Nicole Anziani, MS, RD, CDN, CDE ; with introduction and medical review by Francesco Celi, MD, MHSC.

Description: Chicago, IL : Academy of Nutrition and Dietetics, [2020] | Includes bibliographical references and index. |

Summary: "This comprehensive reference provides guidance for dietitians, physicians, and other allied care professionals working with patients with thyroid disease. Using the most current evidence based guidelines from the American Thyroid Association, the American Association of Clinical Endocrinologists, and available research, this guide addresses: Thyroid function, weight regulation, and the role of iodine Energy and nutrient requirements in thyroid disease Diagnosis, medical management, and applying the Nutrition Care Process to provide patient centered nutrition care of hypothyroidism, hyperthyroidism, and thyroid cancer Awareness of additional interventions, including alternative treatments Working with special populations, related conditions and issues, and prevention strategies Useful appendix materials include sample food plans, low iodine diet guidelines, list of goitrogens, monitoring recommendations, suggested resources, and more"-- Provided by publisher.

Identifiers: LCCN 2020003212 (print) | LCCN 2020003213 (ebook) | ISBN 9780880910194 (paperback) | ISBN 9780880910224 (ebook)

Subjects: LCSH: Thyroid gland--Diseases--Diet therapy.

Classification: LCC RC655 .A58 2020 (print) | LCC RC655 (ebook) | DDC 616.4/40654--dc23

LC record available at <https://lcn.loc.gov/2020003212>

LC ebook record available at <https://lcn.loc.gov/2020003213>

Contents

	List of Boxes, Tables, and Figures	v
	Frequently Used Terms and Abbreviations.....	ix
	Reviewers	xiii
	Preface.....	xv
	Acknowledgments	xvii
	About the Authors	xix
	Special Note	xxi
	Introduction.....	xxiii
SECTION 1	Chapter 1 Overview of the Thyroid and Its Function	2
Introduction to Thyroid	Chapter 2 Thyroid and Weight Regulation	15
Disorders	Chapter 3 Energy and Nutrient Requirements in Thyroid Disease	29
	Chapter 4 Iodine and Its Role in Thyroid Management	36
SECTION 2	Chapter 5 Signs and Symptoms, Risk Factors, and Etiology of	
Hypothyroidism	Hypothyroidism	42
	Chapter 6 Medical Management of Hypothyroidism	48
	Chapter 7 Medical Nutrition Therapy and Nutrition Recommendations for	
	Hypothyroidism	61
	Chapter 8 Alternative Treatments for Hypothyroidism	87
SECTION 3	Chapter 9 Signs and Symptoms, Risk Factors, and Etiology of	
Hyperthyroidism	Hyperthyroidism	92
	Chapter 10 Medical Management of Hyperthyroidism	99
	Chapter 11 Medical Nutrition Therapy and Nutrition Recommendations for	
	Hyperthyroidism	110
	Chapter 12 Alternative Treatments for Hyperthyroidism	131
SECTION 4	Chapter 13 Signs and Symptoms, Risk Factors, and Etiology of	
Thyroid Cancer	Thyroid Cancer	136
	Chapter 14 Medical Management of Thyroid Cancer	139
	Chapter 15 Medical Nutrition Therapy and Nutrition Recommendations for	
	Thyroid Cancer	144
	Chapter 16 Alternative Treatments for Thyroid Cancer	166

CONTENTS

SECTION 5	Chapter 17	Special Populations: Prepregnancy, Prenatal, Postpartum/ Lactation, Elderly, and Pediatric	170
Additional Information for Health Professionals Working with Thyroid Patients	Chapter 18	Managing Additional Concerns and Conditions	189
	Chapter 19	Prevention of Thyroid Conditions	205
SECTION 6	Appendix A	Web, Print, and Other Resources	210
Appendixes	Appendix B	Drugs, Foods, Supplements, and Conditions Affecting Thyroid Medication Absorption and Thyroid Function Tests	214
	Appendix C	Goitrogens	215
	Appendix D	Low-Iodine Diet	216
	Appendix E	Sample Food Plans (Low-Glycemic, Gluten-Free, Anti- Inflammatory, Autoimmune Paleo	220
	Appendix F	Self-Check of the Neck	224
	Appendix G	Quick Guide to Follow-Up Cadence and Monitoring Recommendations	225
		Continuing Professional Education	229
		Index	230

SAMPLE PRINT
Not for Resale

List of Boxes, Tables, and Figures

BOXES	Box 1.1	Potential Challenges to Treatment Based on Thyroid-Stimulating Hormone Levels	6
	Box 1.2	Additional Information Regarding Thyroid Hormone Levels	7
	Box 1.3	Lab Definitions and Interpretation	7
	Box 1.4	The Nutrition Care Process	11
	Box 2.1	Research on Thyroid Medications and Weight Management	19
	Box 2.2	Optimization of Diet for Weight Management with Thyroid Imbalance	19
	Box 2.3	Optimization of Physical Activity for Weight Management in Thyroid Imbalance	20
	Box 2.4	Physical Activity Strategies for Weight Loss and Prevention of Weight Regain for Adults	21
	Box 4.1	Dietary Allowances and Tolerable Upper Intake Level for Iodine . . .	37
	Box 4.2	How Iodine Levels May Present in Thyroid Patients	37
	Box 5.1	Signs and Symptoms of Hypothyroidism	42
	Box 6.1	Conditions that Warrant Thyroid-Stimulating Hormone Screening . .	48
	Box 6.2	Complications of Untreated or Undertreated Hypothyroidism	49
	Box 7.1	Food- or Nutrition-Related History and Hypothyroidism, Hashimoto Disease, and Endemic Goiter	62
	Box 7.2	Sample Laboratory Data for Hypothyroid Patients	66
	Box 7.3	Hypothyroid Nutrition-Related Intake Diagnoses and PES Statements	68
	Box 7.4	Hypothyroid Nutrition-Related Clinical Diagnoses and PES Statements	70
	Box 7.5	Hypothyroid Nutrition-Related Behavioral–Environmental Diagnoses and PES Statements	71
	Box 7.6	Nutrition Intervention Goals for Hypothyroidism	73
	Box 7.7	Medical Nutrition Therapy for Intestinal Permeability in Hashimoto Disease	78
	Box 7.8	Sample Nutrition Prescriptions in Hypothyroidism, Hashimoto Disease, and Endemic Goiter	80
	Box 7.9	Nutrition Monitoring and Evaluation of Adult Hypothyroid Patients	83
	Box 8.1	Supplements Common to Hypothyroidism	88
	Box 9.1	Signs and Symptoms of Hyperthyroidism	93

LIST OF BOXES, TABLES, AND FIGURES

Box 10.1	Complications of Untreated Hyperthyroidism	101
Box 10.2	Medications for Hyperthyroidism	104
Box 10.3	Monitoring of Medical Treatment	107
Box 11.1	Food- or Nutrition-Related History for Hyperthyroidism and Graves Disease	111
Box 11.2	Sample Laboratory Data for Hyperthyroid Patients	114
Box 11.3	Hyperthyroid Nutrition-Related Intake Diagnoses and PES Statements	117
Box 11.4	Hyperthyroid Nutrition-Related Clinical Diagnoses and PES Statements	119
Box 11.5	Hyperthyroid Nutrition-Related Behavioral–Environmental Diagnoses and PES Statements	120
Box 11.6	Nutrition Intervention Steps for Hyperthyroidism	121
Box 11.7	Sample Nutrition Prescriptions in Hyperthyroidism and Graves Disease	126
Box 11.8	Nutrition Monitoring and Evaluation of Adult Hyperthyroid Patients	128
Box 14.1	Risk Stratification of Death from Thyroid Cancer	140
Box 15.1	Food- or Nutrition-Related History for Nodules and Thyroid Cancer	145
Box 15.2	Sample Laboratory Snapshot with Clinical History/Assessment Criteria for Thyroid Cancer	149
Box 15.3	Thyroid Cancer Nutrition-Related Intake Diagnoses and PES Statements	151
Box 15.4	Thyroid Cancer Nutrition-Related Clinical Diagnosis and PES Statements	153
Box 15.5	Thyroid Cancer Nutrition-Related Behavioral–Environmental Diagnoses and PES Statements	154
Box 15.6	Foods to Avoid on a Low-Iodine Diet	157
Box 15.7	Potential Complications of Radioactive Iodine and Nutritional Strategies	158
Box 15.8	Sample Nutrition Prescriptions for Thyroid Nodules and Thyroid Cancer	160
Box 15.9	Nutrition Monitoring and Evaluation of Adult Patients with Thyroid Nodules and Thyroid Cancer	163
Box 17.1	Concerns for Treatment Options Used for Graves Disease in Pediatric Patients	182
Box 17.2	Thyroid Cancer Types and Follow-Up Recommendations in Pediatric Patients	185
Box 19.1	Food and Lifestyle Practices to Promote Thyroid Health and Prevent Disease	207

TABLES

Table 1.1	Level of Thyroid-Stimulating Hormone with Interpretation and Expected Hormonal Profile	5
Table 1.2	Typical vs Other Lab Ranges	10
Table 2.1	Hormones, Weight Regulation, and Relationship to the Thyroid	16
Table 3.1	Activity and Stress/Injury Factors	30
Table 3.2	Quick Estimations for Energy Needs	30
Table 3.3	Daily Protein Requirements	31
Table 3.4	Dietary Reference Intake Method of Estimating Fluid Requirements for Healthy Adults	32
Table 3.5	Selected Recommended Dietary Allowances/Adequate Intake and Tolerable Upper Intake Levels of Nutrients, and How They May Present in Thyroid Patients	33
Table 4.1	Recommended Intake of Iodine in Different Populations	39
Table 6.1	Medication Options for Treating Hypothyroidism	50
Table 6.2	Thyroid Conditions and Medication Dosing	55
Table 6.3	Conversion of Thyroid Medications	56
Table 7.1	Lab Ranges to Test for Hypothyroidism and Hashimoto Disease	64
Table 7.2	Hemoglobin Values and Interpretation for Anemia	65
Table 11.1	Optimal Lab Ranges to Test for Hyperthyroidism and Graves Disease	113
Table 17.1	American Thyroid Association Trimester-Specific Thyroid-Stimulating Hormone Guidelines	172
Table 17.2	Recommended Intake of Iodine in Different Populations	178
Table 17.3	Urinary Iodine Levels	178
Table 17.4	Levothyroxine Needs Based on Age	179
Table 17.5	Dosing of Methimazole in Pediatric Patients	182

FIGURES

Figure 1.1	Thyroid Anatomy	2
Figure 1.2	Hormonal Interplay Among the Hypothalamus, Pituitary Gland, and Thyroid	3

Frequently Used Terms and Abbreviations

AACE	American Association of Clinical Endocrinologists
AAFP	American Academy of Family Physicians
ACE	angiotensin converting enzyme
ACTH	adrenocorticotrophic hormone
ADH	antidiuretic hormone
AI	Adequate Intake
AICR	American Institute for Cancer Research
AITD	autoimmune thyroiditis
AJCC	American Joint Committee on Cancer
AN	anorexia nervosa
ASPEN	American Society for Parenteral and Enteral Nutrition
ATA	American Thyroid Association
ATD	antithyroid drugs
BEE	basal energy expenditure
BIA	bioelectrical impedance analysis
BMI	body mass index
BN	bulimia nervosa
BPA	bisphenol-A
CEA	carcinoembryonic antigen
CH	congenital hypothyroidism
CI EBNPG	Critical Illness Evidence-Based Nutrition Practice Guidelines
CLA	conjugated linoleic acid
CLT	chronic lymphocytic thyroiditis
CPK	creatine phosphokinase
CRP	C-reactive protein test
D3	type 3 iodothyronine deiodinase
DEXA	dual energy x-ray absorptiometry
DKA	diabetic ketoacidosis
DRI	Dietary Reference Intakes
DTC	differentiated thyroid cancer
DTE	desiccated thyroid extract
DV	Daily Value

FREQUENTLY USED TERMS AND ABBREVIATIONS

EDNOS	eating disorder not otherwise specified
EGCG	epigallocatechin gallate
FDA	US Food and Drug Administration
FNA	fine needle aspiration (biopsy)
FODMAPs	fermentable oligosaccharides, disaccharides , and monosaccharides and polyols
FSH	follicle-stimulating hormone
FT3	free triiodothyronine (T3)
FT4	free thyroxine (T4)
GD	Graves disease
GFR	glomerular filtration rate
GH	growth hormone
GI	gastrointestinal
GO	Graves ophthalmopathy
H/H	hemoglobin/hematocrit
HBE	Harris-Benedict equation
hCG	human chorionic gonadotropin
HCTZ	hydrochlorothiazide
HIIT	high-intensity interval training
HPA	hypothalamic-pituitary-adrenal
HPT	hypothalamic-pituitary-thyroid
HRT	hormone replacement therapy
HSL	hormone-sensitive lipase
IBS	irritable bowel syndrome
IgE	immunoglobulin E
IgG	immunoglobulin G
IIH	iodine-induced hyperthyroidism
LBM	lean body mass
LC-MS/MS	liquid chromatography–tandem mass spectrometry
LDN	low-dose naltrexone
LH	luteinizing hormone
LLLT	low-level laser therapy
LPL	lipoprotein lipase
L-T3	liothyronine
L-T4	levothyroxine
MCTs	medium-chain triglycerides
MCV	mean corpuscular volume
MI	myo-inositol
MMA	methylmalonic acid
MMI	methimazole

MMP	matrix metalloproteinase
MNT	medical nutrition therapy
MTC	medullary thyroid cancer/carcinoma
MTHFR	methylenetetrahydrofolate reductase
NAC	N-acetylcysteine
NCP	Nutrition Care Process
NIH	National Institutes of Health
OH	overt hypothyroidism
PCOS	polycystic ovary syndrome
PES	problem, etiology, signs and symptoms statements
PFASs	perfluoroalkyl and polyfluoroalkyl substances
PTH	parathyroid hormone
PTU	propylthiouracil
RAI	radioactive iodine
RCT	randomized controlled trial
RDA	Recommended Dietary Allowance
RDW	red blood cell distribution width
rhTSH	recombinant human TSH
RMR	resting metabolic rate
RT3	reverse triiodothyronine (T3)
RxWBS	post-treatment whole body scan
SCH	subclinical hypothyroidism
SH	subclinical hyperthyroidism
SHBG	sex hormone binding globulin
SIBO	small intestinal bacterial overgrowth
SSKI	potassium iodide
T1	monoiodothyronine
T2	diiodothyronine
T3	triiodothyronine
T4	thyroxine
TA	toxic adenoma
TAb	thyroid antibody
TBG	thyroxine-binding globulin
TBII	thyrotropin-binding inhibitory immunoglobulin
TEE	total energy expenditure
TFT	thyroid function test
Tg	thyroglobulin
TgAb	thyroglobulin antibody
TIBC	total iron binding capacity
TMNG	toxic multinodular goiter

FREQUENTLY USED TERMS AND ABBREVIATIONS

TPO	thyroid peroxidase/thyroperoxidase
TPOAb	thyroid peroxidase antibody
TRAb	thyroid stimulating hormone receptor antibody
TRH	thyrotropin-releasing hormone
TSH	thyroid-stimulating hormone
TSI	thyroid stimulating immunoglobulin
TT	total thyroidectomy
TT3	total triiodothyronine (T3)
TT4	total thyroxine (T4)
TTR	transthyretin
UBW	usual body weight
UICC	Union for International Cancer Control
UL	Tolerable Upper Intake Level
US	ultrasound
WBS	whole body scan

Reviewers

Sheila Dean, DSc, RDN, LDN, IFMCP

Co-founder, Integrative and Functional Nutrition Academy
Palm Harbor, FL

Lori Enriquez, MPH, RDN, LDN, CHES, FAND

Nutrition and Health Consultant, Eat Fit Health, LLC
King of Prussia, PA

Nicole German Morgan, RDN, LD, CLT

Registered Dietitian Nutritionist, Nicole's Nutrition, LLC dba Thyroid Dietitian
Bradenton, FL

Cheryl Harris, MPH, RD

Owner, Harris Whole Health
Fairfax, VA

Nancy Jolliffe, RD, CSO, LD

Clinical Dietitian II, Hall-Perrine Cancer Center
Cedar Rapids, IA

Lisa Markley, MS, RDN

Registered Dietitian Nutritionist, Nourish Yourself Nutrition & Wellness
Lenexa, KS

Clara Schneider, MS, RD, RN, LDN, CDE

Diabetes Educator
Corolla, NC, and Alameda, CA

Preface

This book is intended mainly for the health care professional and, in that vein, is written using scientific and medical language. I would ask health professionals using this book to approach the nutrition care of thyroid patients with an open mind. Thyroid care is nuanced—no two patients are the same, and each person will present with a different set of clinical parameters and reported symptoms. This book, which contains a wealth of available evidence-based practices and potential interventions at the time of writing, provides guidance for health care practitioners such as physicians, dietitians, and all other allied care professionals working with patients with thyroid disease. My hope is that once a patient has tried “everything” yet still doesn’t feel “right,” this book will help us as providers to determine additional options to better help them. This book is intended as both a time-saver and a guide, matching nutrition care with medical care, but with the understanding that research will continue to refine and improve recommendations over time.

Throughout the writing and revision phases, I have tried to provide a balanced account of the available research, citing evidence-based guidelines from the American Thyroid Association (ATA) and the American Association of Clinical Endocrinologists (AACE), as well as citing numerous other research studies. I have based the framework of nutrition care on the Academy of Nutrition and Dietetics Nutrition Care Process (NCP). You will also find information from several evidence-based integrative and functional medicine resources included within. Peer reviewers weighed in to help ensure that content was relevant, up-to-date, and useful for practitioners.

Although evidence will continue to evolve from ongoing research, we must remember that our patients are people, not study subjects. There may not yet be robust research to demonstrate every potential benefit that practitioners might see for each intervention. My hope is that this book helps provide a fluid set of recommendations that are subject to change based on the available research. There is controversy in the subject of thyroid care; therefore, there are times where a provider may need to use clinical judgment to supersede the overarching recommendations and use innovative interventions, though keeping a patient’s safety in mind is of primary importance in any of these decisions.

The main premise I wish to urge is that we focus on patient-centered care—listening closely to our patients, taking time and giving the attention needed to find the best course of action for each patient, one thyroid at a time.

Nicole Anziani, MS, RD, CDN, CDCES
Brooklyn, New York

Acknowledgments

I dedicate this work to my parents.

I wish to thank:

Debbie—my mother and the only person in my family to buy a book about thyroid when I was struggling, who called me to say, “I’m on page 108. I know all about you now. Oy ... the hormones!” In 2015, while I was writing this book, my mother had a stroke. Much of this manuscript was written in her hospital room over a period of months. She constantly encouraged me to write, even when I was her caretaker. Thank you, *Bella*, for calling me your author.

Raul, my father and first editor—you’ve always encouraged me and believed in my abilities more than I did. You’ve shared in every triumph and struggle in my life. You were the first person I saw when I opened my eyes after surgery and the only one who offered to make me soup. I have endless appreciation for you and hope this makes you proud.

Grandma Mickey—along with my parents, you jumped around your kitchen doorway when the proposal for this book was approved. Thank you for being.

My paternal grandma, Elba Anziani, *Mamita*—you watched from the spirit realm as I wrote each word.

My brother Reuben “Madhu”—for providing me with healing (and a BioMat to write on) when my stress level was high.

My cousins J. Javier Anziani, JD, and Andre Anziani, JD, LLM, who provided contract expertise and advice.

Vanessa Alvarez, MS, RD—one of the best dietitians (and people) I know, whose empathy is unparalleled. You are part of the reason I am a dietitian today. Love you, my sister.

Jamillah Hoy Rosas, MPH, RD, CDCES—you were my first registered dietitian nutritionist boss and advisor in academic research at New York University. You always had faith in me, offering so many professional opportunities throughout my career. I will always look up to you as a mentor in the field.

Heather Perillo, MS, RD, CDN—you were a prime example of what a dietitian should aspire to be, first as my preceptor and later my colleague. Your training shaped my work and I thank you for having been my reference all these years.

All other instrumental mentors or dietitians in my academic life—including, but not limited to: Robert Fabini; Joan Cone; Christopher Dolder; Joan Thompson, PhD, MPH, RD, CDCES; Mary Mead, MEd, RD, CDCES; Nancy Hudson, PhD (Hon), MS, RD; Domingo Piñero, PhD; Antionette Franklin, MS, RD, CDN; Lisa Garback Garner, MS, RD, CDN; Mary Ellen Kelly, MS, RDN, CSSD, LDN; Pamela Purcell, MS, RD, CNSC, LDN; Eileen Ostrander, MS, RD, CDN; Cynthia Floyd, MS, RD, CDN, CDCES; Valerie L. Thomas, MS, RD, CDN; and Cindy Sizemore, MS, RD, LD.

The reviewers of this publication—thank you so much for your meticulous work and valuable comments that have made this publication a quality one.

ACKNOWLEDGMENTS

Francesco Celi, MD, MHSc—your time and expertise as medical reviewer of this work is tremendously appreciated. Thank you for your contribution to thyroid research and for making this project stronger in so many ways.

The Academy of Nutrition and Dietetics—for taking on this project, and for your willingness to bring controversial information to light for the benefit of health professionals and patients alike.

Arlene Bregman, DrPh—for your organization of the local ThyCa meetings in NYC.

Yan Qi, PhD, and Liza Wong—for your suggestions and sharing conference notes.

Jaime Schehr, ND, RD—for pointing me to Dietitians in Integrative and Functional Medicine and the Natural Medicines Database for evidence-based research on dietary supplements.

Jennifer Trevillian and April Conlon, PharmD—for sharing resources and your personal journeys with me.

Anne Eller, PhD—for helping me understand the review process and sitting with me as I read the first set of reviews. Thanks for your expert insight!

Mally—you were one of the first to congratulate me on this project and sent motivational raps for the writing process. Thank you!

The B-School focus group who helped inspire the proposal for this book—Christine Gutierrez, LMHC; Tatiana Dellepiane; Dominick Quartuccio; Bertina Lee; Jennifer Spivak; Michelle Shemilt; and the memory of Jamie Lauren Zimmerman.

My friends and former coworkers at 185th Street, who made me feel like a rock star when they found out about this book—namely, Kimone Gilphilin, MS, RN; Lisa Calandra, DPM; Marlene Velez; and Danny Vairo.

All my colleagues at Cecelia Health—for your daily support.

The doctors who have helped me in my personal thyroid experience—Marc A. Cohen, MD, MPH; Arthur Spokojny, MD (RIP), and his medical staff (Sherine Smith); Naina Marballi, BASM; Alla Khalfin, DO; Maurice Beer, MD; Robin Berzin, MD; Lilli Link, MD; and Rekha Kumar, MD, MS. Each of you, in your own way, saved my life. How can I possibly thank you?

The most inspirational thought leaders I've encountered on my personal journey with thyroid cancer—Kris Carr; Terri Cole, LCSW; Sara Gottfried, MD; and Alan Christianson, ND—your work and vision have all contributed to my work. You've given me a reason to get up in the morning, permission to live without fear, and a fire to learn and hope for a better future.

Jancarlo—at the start of this project, your work ethic inspired mine; as the project continued, your laughter medicine became just as vital as my thyroid medicine. Thank you for your partnership and love.

All the souls I've had the privilege to work with, share time with, and learn from, and my community of friends and family—thank you for encouraging my medical and writing journeys. Your support has kept me truly alive.

About the Authors

Nicole Anziani, MS, RD, CDN, CDCES, received her bachelor's degree in nutrition and dietetics from the University of California at Berkeley and completed her dietetic internship at the James J. Peters VA Medical Center in the Bronx, NY, coordinated with a master of science in clinical dietetics from New York University. She is a registered dietitian licensed in New York, a certified diabetes care and education specialist, and certified as a personal trainer, group fitness instructor, Ayurvedic wellness counselor, and reiki practitioner. As a thyroid cancer survivor, Anziani's passion and mission is to make nutrition care information for thyroid conditions easily accessible to practitioners and patients. Born and raised in Richmond, CA, Anziani now lives and works remotely via Brooklyn, NY.

Introduction and Medical Review

Francesco S. Celi, MD, MHSc, is the William G. Blackard Professor of Medicine and Chair of the Division of Endocrinology Diabetes and Metabolism at Virginia Commonwealth University in Richmond. Prior to joining the faculty of Virginia Commonwealth University, Celi worked for 10 years as clinical investigator at the National Institute of Diabetes, Digestive, and Kidney Diseases in Bethesda, MD. Celi is a graduate of the University of Rome "La Sapienza," and a diplomate of the Board of Internal Medicine, with subspecialty in endocrinology, diabetes, and metabolism. He was awarded the master's in health sciences by Duke University in Durham, NC. Celi conducts both clinical and translational research and his scientific interest is focused on the physiology and pathophysiology of thyroid hormone action as it relates to energy metabolism. Another area of research is in the mechanisms of adipose tissue differentiation and on the role of hormonal signaling (including thyroid hormone) on promoting differentiation of adipose tissue depots in thermogenic fat and its ability to dissipate energy. Celi has published more than 80 peer-reviewed manuscripts and has been invited to lecture at various institutions across the United States and Europe. Celi's clinical interests are thyroid disease, management of thyroid cancer, and treatment of diabetes.

Special Note

The Academy of Nutrition and Dietetics has adopted the increasingly common practice of dropping possessive apostrophes from the names of diseases and disorders. In alignment with the Endocrine Society, the American Medical Association, the 32nd edition of *Dorland's Illustrated Medical Dictionary*, and new material from National Institutes of Health, the *Health Professional's Guide to Nutrition Management of Thyroid Disease* spells terms such as Graves disease without an apostrophe. Other organizations and older publications may still maintain an apostrophe, but there is no difference in meaning between Graves disease and Graves' disease or Hashimoto thyroiditis and Hashimoto's thyroiditis.

SAMPLE
Not for
or Resale

Introduction

Francesco S. Celi, MD, MHSc

The action of thyroid hormone affects virtually all tissues of an organism, and it plays a critical role in the modulation of energy metabolism. Indeed, the dramatic effects of overt thyroid disease—particularly hyperthyroidism—on body weight and composition are valuable examples of the critical role hormones play in the regulation of metabolism. Aside from energy metabolism, thyroid hormone action affects other critical systems in an organism: first and foremost, the central nervous system, both during development and throughout adult life. Thyroid hormone action is also particularly important for bone growth and remodeling, as well for skeletal muscle development and function. Collectively, the action of thyroid hormone is pervasive, and its regulation is crucial for maintenance of body functions.

Disorders affecting the thyroid gland—both function and tumors—are very common in the general population and are disproportionately frequent in women. Although the symptomatology associated with overt thyroid dysfunction is quite characteristic and easily recognizable, most patients with thyroid disorders are affected by mild forms of thyroid dysfunction, with symptoms and signs that are often vague and aspecific. As individuals age, the prevalence of thyroid dysfunction can be as high as 12%, and population studies indicate that thyroid nodules are also very common. Increasing availability of sophisticated diagnostic tools and more widespread use of thyroid ultrasound has contributed to the increased frequency of diagnoses of thyroid dysfunction, nodules, and cancer in recent years.

This increase in diagnoses of thyroid pathology has been mirrored by an increase in awareness among the general public of the role (whether real or perceived) that thyroid function plays regarding an individual's sense of well-being. This has progressed to the point that assessment of thyroid function is one of the first steps providers undertake while evaluating symptomatology that is not clear and that may have overlap with other chronic conditions. As a consequence, thyroid disease and dysfunction are very common concerns among patients and providers, and, quite often, both parties share the notion that subclinical or unrecognized thyroid dysfunction may be the root cause of otherwise unexplained symptoms. As a consequence, modulation of thyroid function, via either therapy or dietary supplements, is often employed to address a variety of conditions, particularly those involving weight gain, low energy, chronic fatigue, and depression.

Against this background of increased awareness and, in some cases, perhaps excessive expectations, it's important to consider that the thyroid gland and its function is heavily affected by nutrition and adequate delivery of oligo-elements: in particular, iodine and selenium. In fact, iodine deficiency represents the most common preventable cause of intellectual disabilities worldwide. Although the United States is considered an iodine-sufficient area, some conditions and dietary habits can significantly impact iodine intake, resulting in iodine deficiency. Thyroid pathology itself, in either the acute or recovery phase of disease,

often requires nutritional intervention to optimize the healing process and to prevent additional morbidity.

Some lay literature and a substantial number of practitioners—particularly in the fields of alternative and complementary medicine—strongly support using nutritional supplements and modification of diet to optimize thyroid function, either by addressing nutritional deficiencies or stimulating immune function. Although the empirical evidence of this in humans is marginal and of limited quality, it is important to note that *in vitro* experiments and mechanistic studies carried out in laboratory animal or cell culture systems have indicated that nutrition and oligo-element supplementation play roles in the pathophysiology of the thyroid. While this is important, it's also important to recognize the knowledge gap between findings in experimental models and clinical relevance in patients.

The *Health Professional's Guide to Nutrition Management of Thyroid Disease* takes a unique course by defining the role of nutrition and dietary supplementation in thyroid physiology and pathology. By systematically defining the various physiologic states and pathologic conditions affecting the thyroid, this book provides relevant information on the potential roles of nutrition intervention and use of dietary supplements. It strives to define the mechanistic rationale for such interventions; whenever possible, it provides references to relevant human studies. It provides references to guidelines of leading professional organizations that are dedicated to the study and care of thyroid disease, and it recognizes the gaps in knowledge of the effects of nutritional interventions and dietary supplementation that exist in relation to thyroid disorders.

This book's systematic approach to the topic and its extensive references to high-quality published research make it a useful reference for nutritionists and practitioners alike. At the same time, each chapter's introduction provides a good framework of the problem presented, which enables a nonmedical audience to better understand the roles nutrition and dietary supplementation can serve in the amelioration of thyroid disease, all while maintaining realistic expectations. Finally, the extensive references and resources herein provide a comprehensive tool set to help readers further deepen their knowledge of the interactions among nutrition, dietary supplementation, and thyroid function.

SECTION 1

Introduction to Thyroid Disorders

CHAPTER 1

Overview of the Thyroid and Its Function

2

CHAPTER 2

Thyroid and Weight Regulation

15

CHAPTER 3

Energy and Nutrient Requirements in Thyroid Disease

29

CHAPTER 4

Iodine and Its Role in Thyroid Management

36

1


INTRODUCTION

Overview of the Thyroid and Its Function

The thyroid is a butterfly-shaped endocrine gland weighing less than 1 ounce (28 g) in healthy adults and children. It is located in the middle of the lower neck, in front of the trachea (see Figure 1.1).¹ Thyroid hormones regulate the body's metabolism and affect nearly every action of every cell, including such vital functions as heart rate and energy level.^{2,3}

The thyroid works in conjunction with the pituitary gland and the hypothalamus. The hypothalamus, located in the lower central area of the brain, produces thyrotropin-releasing hormone (TRH) in response to external factors and stressors.⁴ TRH travels to the pituitary gland at the base of the brain. There, thyrotropin/thyroid-stimulating hormone (TSH) is produced. TSH is sent to the thyroid gland to regulate thyroid hormone storage, production, and release. Figure 1.2 illustrates the feedback mechanisms of the hypothalamic-pituitary-thyroid (HPT) axis.

FIGURE 1.1
THYROID ANATOMY



5

Signs and Symptoms, Risk Factors, and Etiology of Hypothyroidism

INTRODUCTION AND BACKGROUND

Hypothyroidism, or underactive thyroid, is the most common thyroid disorder. It is thought to affect approximately 4.6% of the US population over age 12,¹ and that estimate increases to as high as 10% outside of the United States.² In hypothyroidism, the thyroid gland does not produce enough thyroid hormones, including triiodothyronine (T3) and thyroxine (T4), to maintain the body's functions. This decreases metabolism, including cell activity and regeneration, and may be related to unintentional weight gain.³ Refer to Chapter 2 for more information regarding thyroid disease and weight regulation.

Hypothyroidism can increase cardiovascular risks and can cause mood changes, fatigue, and gastrointestinal distress, all of which can be barriers to healthy lifestyle changes. The health or nutrition professional is challenged with the task of helping patients set realistic goals for diet and exercise while taking into account possible micronutrient deficiencies and interactions between thyroid medications, foods, and supplements. It is important to coordinate with the patient's medical team in order to promote improved outcomes.⁴

SIGNS AND SYMPTOMS

There are many potential physical and mental symptoms of hypothyroidism. Not all symptoms are present in every patient, and some patients may not exhibit any symptoms; some can also be subtle, especially in subclinical hypothyroidism (SCH).⁵ It is important to note that many hypothyroid symptoms overlap with those seen in other chronic conditions. Box 5.1 summarizes some common signs and symptoms of hypothyroidism.

BOX 5.1 SIGNS AND SYMPTOMS OF HYPOTHYROIDISM⁵⁻⁹

Physical Symptoms of Hypothyroidism

Brittle nails	Fatigue	Joint pain
Chronic sinusitis	Goiter	Mood swings
Constipation	Hair loss	Muscle cramps
Decreased libido	Hearing loss	Puffiness of hands and face
Decreased perspiration	Heavy and irregular menses	Slowed ankle-reflex relaxation time
Difficulty losing weight	Hoarse voice or voice changes	Slowed speech
Dry and coarse skin	Infertility	Small thyroid gland
Dry and gritty eyes	Insomnia	Tinnitus
Enlarged neck	Intolerance to cold	Weight gain

continued on next page

BOX 5.1 SIGNS AND SYMPTOMS OF HYPOTHYROIDISM⁵⁻⁹ (continued)**Mental Symptoms of Hypothyroidism**

Brain fog
 Confusion
 Depression
 Difficulty thinking and concentrating
 Irritability
 Memory impairment
 Mental apathy

Symptoms of Severe Hypothyroidism

Carpal tunnel syndrome
 Elevated lipids
 Hyponatremia can arise within several weeks of onset
 Pituitary hyperplasia with or without hyperprolactinemia and galactorrhea
 Serum creatine kinase and other muscle/hepatic enzymes may be abnormal
 Sleep apnea

RISK FACTORS

The following factors may predispose a person to hypothyroidism:

- **Personal history of a thyroid problem**, such as goiter or nodules.¹
- **Personal history of postpartum thyroiditis or autoimmune thyroid disease** (eg, Hashimoto thyroiditis*).
- **Family history of thyroid disease**, which increases the risk of developing autoimmune thyroid disease. Studies have shown that up to 60% of first-degree relatives of people with autoimmune thyroid disease also have thyroid antibodies, which may signal future development of an autoimmune thyroid condition.¹⁰
- **Being Female**; women are five to eight times likelier than men to develop hypothyroidism.⁸ Women with positive antibodies and high thyroid-stimulating hormone (TSH) levels have a higher annual risk (4%) of developing hypothyroidism than those with either factor alone (2% to 3%).⁵
- **Age**; hypothyroidism is more common over the age of 60.¹ As many as one in four patients in long-term care may have undiagnosed hypothyroidism.¹¹
- **Autoimmune diseases and endocrine disorders**, both in personal or family history, such as lupus, Sjögren syndrome, pernicious anemia, type 1 diabetes, celiac disease, rheumatoid arthritis, Addison disease, or polycystic ovary syndrome.¹
- **Turner syndrome**, a genetic disorder in females.¹
- **Being pregnant or up to 6 months postpartum**¹; additionally, other hormonal imbalances and menopause can initiate thyroid imbalances.
- **Receiving radiation to the thyroid, neck, or chest**.¹

ETIOLOGY

There are several causes of hypothyroidism, which can be categorized as biological or nonbiological causes.

Biological Causes of Hypothyroidism

Hashimoto disease, otherwise known as chronic lymphocytic thyroiditis, autoimmune thyroiditis, or Hashimoto thyroiditis, is an autoimmune disorder¹² that is the most common cause of hypothyroidism in the United States.¹ Hashimoto disease, which may cause more than half of hypothyroidism cases in North America, is most common in women between 30 and 50 years of age.¹²

* The Academy of Nutrition and Dietetics has adopted the increasingly common practice of dropping possessive apostrophes from the names of diseases and disorders. Please see Special Note on page xxi for more information.

Inflammation of the thyroid gland from an autoimmune attack can lead to excess thyroid hormone production and a hyperthyroid state¹³ known as hashitoxicosis. This inflammation can lead to destruction of the thyroid gland and a gradual inability to produce thyroid hormones. As this develops, the pituitary gland releases TSH in increasing amounts to signal the thyroid to produce more hormones. In some cases, this may lead to a goiter or an enlarged thyroid gland.⁹

Experts suggest that this may be triggered by a buildup of environmental toxins in the thyroid, intestinal permeability, gluten and casein in the diet, drops in blood glucose, stress, and other infections or inflammation causing stimulation of T-helper cells or lymphocytes (Th1 or Th2). Practitioners have found that treating these root causes may halt the disease process,⁹ but experimental evidence is needed.

Thyroiditis is inflammation of the thyroid gland that is often caused by autoimmunity or infection. In some cases, hormone secretion is increased, leading to 1 or 2 months of thyrotoxicosis.¹² The damage caused from the ensuing inflammation can lead to hypothyroidism¹ or can resolve spontaneously.

Reidel thyroiditis is a rare, chronic inflammatory disease of the thyroid gland in which dense fibrosis replaces normal thyroid tissue. It may permanently damage the thyroid, causing hypothyroidism in 30% of cases.¹⁴ In de Quervain thyroiditis, the thyroid gland rapidly swells and is painful and tender.¹⁵ The patient experiences no pain in instances of silent thyroiditis.¹⁶

Ord disease is a type of autoimmune thyroid disease that does not involve development of a goiter. Some researchers consider it to be part of the same disorder as Hashimoto disease.¹⁷

Postpartum thyroiditis, discussed in more detail in Chapter 17, has three possible outcomes. It may cause transient thyrotoxicosis in the mother, which resolves. It may cause transient hypothyroidism following transient thyrotoxicosis in the mother, and both subsequently resolve. Last, it may develop into a type of Hashimoto thyroiditis in which hypothyroidism in the postpartum period progresses into overt hypothyroidism.¹⁸

Genetic causes; several genes affect normal fetal thyroid development,¹⁹ with some decreasing even a normal thyroid's ability to produce thyroid hormones.²⁰ Congenital hypothyroidism, in which a child is born with partial or total loss of thyroid function, occurs when there are mutations in the DUOX2, PAX8, SLC5A5, TG, TPO, TSHB, and TSHR genes. This affects one in every 3,000 to 4,000 newborns, is inherited 15% to 20% of the time,²¹ and can lead to intellectual disabilities and growth failure. For this reason, most newborns in the United States are screened for hypothyroidism, as early treatment can prevent complications (this is discussed in further detail in Chapter 17).¹ The vast majority of cases of congenital hypothyroidism have unknown genetic causes.

Pituitary and hypothalamic disorders; normally, the hypothalamus stimulates the pituitary gland to make TSH. Malfunctions in these mechanisms can result in hypothyroidism.²² It is believed that as many as 1 in 10 adults worldwide has an adenoma, or benign tumor of the pituitary gland, yet many of these tumors do not cause harm or secrete hormones (those with no clinical impact are commonly referred to as incidentalomas). Rarely, pituitary

choose to use a compounding pharmacy, the pharmacy should meet stringent quality standards, such as holding a sterile compounding pharmacy license.

How to Dose Medications

When a health professional initiates thyroid replacement therapy, the ATA recommends that a “patient’s weight, lean body mass, pregnancy status, etiology of hypothyroidism, degree of TSH elevation, age, and general clinical context, including the presence of cardiac disease,” along with the TSH goal, should be taken into account. Patients with a goal of TSH suppression generally require more thyroid hormone replacement; those whose thyroids have been completely removed generally need more than Hashimoto patients. Patients who have received radioactive iodine ablation for Graves disease may need varying amounts depending on residual thyroid function post-treatment. Patients who have experienced a significant change in weight, who are aging, who are pregnant, or who have changed their thyroid dosage should have blood work reassessed in 4 to 6 weeks.⁶ Table 6.2 includes initiation and dosing recommendations for several subsets of patients.

TABLE 6.2 THYROID CONDITIONS AND MEDICATION DOSING^{1,6}

Patient Profile	L-T4 Dose (per kg body weight)	Thyroid-Stimulating Hormone Goal	How to Initiate and Progress Therapy
Minimal endogenous thyroid function in middle-aged patients	1.6-1.8 µg/kg actual body weight 2.0-2.1 µg/kg for some patients Some use ideal vs actual body weight	0.5-2.0 mIU/L for good balance	Initiate at full dose
Thyroid cancer patients	2.1-2.7 µg/kg	Thyroid-stimulating hormone (TSH) suppression, or individualized to address prognosis/type of cancer	Initiate at full dose
Mild hypothyroidism: serum TSH ≤10 mIU/L in young and middle-aged patients	–	0.5-2.0 mIU/L for good balance	Initiate at full dose, usually 25-75 µg/d (not weight-based therapy)
Elderly patients over age 65 (less lean body mass, less hormone need)	–	Higher serum TSH goal range 4-6 mIU/L in those >70 years of age	Start low and go slow: generally initiate at 50 µg, and adjust by 12.5-25 µg/d up or down depending on TSH
Cardiac patients with coronary artery disease	–	0.5-3.5 or 4 mIU/L, per American Thyroid Association	Start low and go slow: gradual increases based on TSH and symptoms, with adjustments of 12.5-25 µg/d
Patients who are severely hypothyroid after treatment for hyperthyroidism	Variable	0.5-3.5 or 4 mIU/L	Initiate full dose

of antidepressants to changes in the brain's metabolism of thyroid hormones, suggesting that the use of liothyronine (L-T3) in conjunction with antidepressants may be beneficial.⁵⁷ This has been further studied and confirmed in human studies.^{58,59}

Low thyroid hormone levels can cause residual symptoms that linger post-treatment.⁶⁰ Graves disease (GD) patients have been shown to have a lower quality of life up to 21 years following treatment for hyperthyroidism,⁶¹ and research has shown that 35.6% of patients with GD who have had normalized thyroid levels for over 6 months still experience psychological distress and anxiety, and that 95.6% of them were depressed.⁶² Prevention and education regarding early warning signs, such as changes in sleep, appetite, energy, self-esteem, motivation, concentration, or sexual interest, are recommended.

Nutrition and Lifestyle Approaches to Improve Depression and Mood

Researchers have examined the benefits of several nutrients, supplements, and lifestyle behaviors and their effects on depression. For example, research has shown that increasing n-3 fatty acid consumption helps alleviate depression,⁶³ as does stress management and development of regular sleep patterns.⁶⁴ Nutrient interventions include consuming foods rich in beta-carotene; vitamin C; vitamin E; lean proteins; and complex vs simple carbs, as well as considering a Mediterranean diet overall.⁶⁴ St John's wort has been used as a supplement to manage depression, but it is important to keep in mind that these supplemental therapies should be administered under qualified medical supervision.⁶⁴ Most interventions are not recommended in pregnant or lactating women, and practitioners should exercise caution when working with patients with certain medical conditions or patients taking additional medications. If the RDN or other health care provider wishes to recommend complementary or alternative therapies, more thorough investigation into side effects, food-drug and herb-drug interactions, and contraindications is advised and should be individualized to the patient with the medical team.

FIBROMYALGIA

Fibromyalgia, a chronic and disabling condition characterized by pain, fatigue, stiffness, and multiple tender points, afflicts 2% to 4% of the North American population.⁶⁵ It is thought that central nervous system dysfunction and lifestyle factors, such as sleep difficulties, stress, infection, injury, nervous system changes, changes in muscle metabolism, and a family history, contribute to its development.⁶⁶

In fibromyalgia, a constant low-level activation of the coagulation system has been observed in limited research.⁶⁷ This creates a soluble fibrin monomer (SFM) that coats the inside of blood vessels, limiting oxygen and nutrients from entering the cells. Decreased oxygen may lead to pain, fatigue, and brain fog. SFM development can lead to bacterial growth and infection. These effects can make thyroid hormone less efficient⁶⁸; however, it is important to note that this is a speculative theory.

Some alternative medicine practitioners believe that people with fibromyalgia can be cured or improved by treating the individual with high doses of triiodothyronine (T3) along with nutritional supplements, diet, and exercise.^{69,70} This protocol can be dangerous, however, and is not accepted as a treatment practice. The high T3 dose utilized in one study may induce hyperthyroidism, but a lower dose could still provide benefits with a decreased risk of iatrogenic hyperthyroidism. Fibromyalgia has some links to thyroid disease, including the following:

- One out of every three fibromyalgia patients also has autoimmune thyroid disease.⁷¹

SECTION 6

Appendixes

APPENDIX A

210

Web, Print, and Other Resources

APPENDIX B

214

Drugs, Foods, Supplements, and Conditions Affecting
Thyroid Medication Absorption and Thyroid Function
Tests

APPENDIX C

215

Goitrogens

APPENDIX D

216

Low-Iodine Diet

APPENDIX E

220

Sample Food Plans (Low-Glycemic, Gluten-
Free, Anti-Inflammatory, Autoimmune Paleo)

APPENDIX F

224

Self-Check of the Neck

APPENDIX G

225

Quick Guide to Follow-Up Cadence and Monitoring
Recommendations

APPENDIX

E

Sample Food Plans (Low-Glycemic, Gluten-Free, Anti-Inflammatory, Autoimmune Paleo)

LOW-GLYCEMIC SAMPLE 3-DAY DIET

There are different methods for designing a low-glycemic food plan. The sample 3-day menus for the low-glycemic diet provided here contain:

- Unlimited carbohydrates from low-glycemic vegetables, such as broccoli, asparagus, spinach, chard, kale, cabbage, bok choy, arugula, sea vegetables, and so on. (Note: many of these are goitrogens, so cooking would be preferable to consuming raw.)
- Up to ½ cup of whole grains, such as brown, black, and red rice; quinoa; amaranth; buckwheat; or teff, or up to ½ cup of starchy vegetables such as winter squash, peas, potatoes, corn, and root vegetables, per day.
- Up to ½ cup of legumes, such as lentils, chickpeas, split peas, edamame, black beans, or navy beans per day.
- Up to ½ cup of berries, such as blueberries, cherries, blackberries, and raspberries, per day and/or one to two pieces of apple, pear, or stone fruit, such as plum, peach, or nectarine.
- From 30 to 50 grams of fiber per day.

	BREAKFAST	LUNCH	SNACK	DINNER
DAY 1	Blended shake made with pea protein powder, ½ cup frozen berries, 1 cup unsweetened almond milk, 1 tablespoon flaxseed oil, 1 handful spinach, and 2 teaspoons almond butter	Salad made with ½ can rinsed white beans served over a bed of arugula and topped with 1 small can artichoke hearts; drizzle with extra virgin olive oil and balsamic vinegar and sprinkle with black pepper	1 ounce almonds	4 ounces salmon filet served with ½ cup sweet potato and steamed asparagus drizzled with 2 teaspoons olive oil
DAY 2	2 hard-boiled eggs served on a bed of arugula with ½ cup raspberries on the side	Smoked salmon served with sliced Kirby cucumbers, tomatoes, kalamata olives, and hummus over a bed of romaine lettuce	Turkey slices rolled up in lettuce leaves	Quick sauté over medium heat: ½ cup precooked brown rice; prewashed spinach and kale; 2 teaspoons olive oil; chopped garlic; and 4 ounces canned chicken
DAY 3	Egg-white omelet made with spinach, ¼ avocado, and sliced tomato, served with ½ cup blueberries	½ cup cooked lentil soup with a side salad, ½ avocado, and sliced tomatoes and ½ sliced peach	Celery with almond butter	Chopped tofu and bok choy sautéed in tamari sauce and served over ½ cup quinoa

Continuing Professional Education

This edition of *The Health Professional's Guide to Management of Thyroid Disease* offers readers 8 hours of Continuing Professional Education (CPE) credit. Readers may earn credit by completing the interactive online quiz at the following website: <https://publications.webauthor.com/health-pro-guide-thyroid>

SAMPLE Print
Not for Resale

Index

Page numbers followed by *f* indicate figures, page numbers followed by *t* indicate tables, and page numbers followed by *b* indicate boxes.

- AACE. *See* American Association of Clinical Endocrinologists
- absorption, drug, 53, 214
- Academy of Nutrition and Dietetics, 12, 199
Critical Illness Evidence-Based Nutrition Practice Guidelines, 29
- Achilles reflex test, 66
- acupuncture, 191, 195
- Adequate Intake (AI), 33*t*–34*t*
- administration, food/nutrient
 hyperthyroidism, 111*b*
 hypothyroidism, 62*b*
 thyroid nodules/thyroid cancer, 146*b*
- adolescents, Graves disease in, 181–182
- adrenal fatigue, 20*b*
- adrenal insufficiency. *See* cortisol dysregulation
- aerobic exercise, 21
- AI. *See* Adequate Intake
- AICR. *See* American Institute for Cancer Research
- AITD. *See* autoimmune thyroiditis
- AJCC. *See* American Joint Committee on Cancer
- alcohol ablation, for thyroid cancer, 142
- allergenic foods, 24
- alpha lipoic acid, 25
- alternatives therapies
 for hyperthyroidism, 131–132
 for hypothyroidism, 87–89
 for thyroid cancer, 166–167
- American Academy of Family Physicians, 48
- American Academy of Pediatrics, 181
- American Association of Clinical Endocrinologists (AACE), 4, 48, 52, 54
- American Cancer Society, 136
- American College of Physicians, 48
- American College of Sports Medicine, 20*b*
- American Institute for Cancer Research (AICR), 145
- American Joint Committee on Cancer (AJCC), 140
- American Society for Reproductive Medicine, 171
- American Thyroid Association (ATA), 172*t*
 Guidelines for the Treatment of Hypothyroidism, 15, 54, 58–59
 Practice Guidelines for Hypothyroidism in Adults, 38
- amino acid precursors, 198
- amiodarone-induced thyrotoxicosis, 107
- amitriptyline, 199
- anaplastic carcinoma, 138, 176
- anatabine, 89
- Anatabloc, 89
- anemias, laboratory assessment of, 65, 65*t*
- animal fats, and weight management, 20*b*
- anthropometric assessment
 hyperthyroidism, 113, 128*b*
 hypothyroidism, 63–64, 83*b*
 thyroid cancer, 147, 163*b*
- antidepressants, 26
- anti-inflammatory diet, 122, 123, 207, 222
- antioxidants, and weight management, 25
- antithyroid drugs (ATDs), 99, 100, 103–104, 104*b*, 105, 106, 122, 177
 and postpartum period, 176
 and pregnancy, 175
 use in children, 181, 182*b*–183*b*
- L-arginine, 197
- Armour Thyroid
 conversion of dosages, 56*t*–57*t*
 for hypothyroidism, 52*t*, 77
- artificial sweeteners, 45
- ATA. *See* American Thyroid Association
- ATDs. *See* antithyroid drugs

- autoimmune diseases, 198–199
 and hypothyroidism, 43–44
 thyroid diseases, 43
 triggers for, 77
- autoimmune paleo diet, 199, 223
- autoimmune thyroiditis (AITD), 94
- basal energy expenditure (BEE), 29–30
- B-complex vitamins, 121
- BEE. *See* basal energy expenditure
- behavior
 and hyperthyroidism, 112*b*, 125
 and hypothyroidism, 63*b*, 79
 and thyroid nodules/thyroid cancer, 146*b*, 160
 for weight loss, 22–23
- behavioral–environmental diagnosis
 hyperthyroid nutrition-related, 120*b*
 hypothyroid nutrition-related, 71*b*–72*b*
 thyroid nodule/cancer nutrition-related, 154*b*
- Belviq, 25
- benzodiazepines, 199
- beta-blockers
 for hyperthyroidism, 99, 100, 102, 105, 107
 use in pediatric patients, 183*b*
 and weight gain, 26
- BIA. *See* bioelectrical impedance analysis
- bioactive substances, 81
 and hyperthyroidism, 117*b*, 126*b*
 and hypothyroidism, 68*b*, 80*b*
 and thyroid nodule/cancer, 151*b*, 161*b*
- biochemical domain
 and hyperthyroid nutrition, 119*b*
 and hypothyroid nutrition, 70*b*
 and thyroid nodule/cancer nutrition, 153*b*
- bioelectrical impedance analysis (BIA), 64, 147
- bioidentical progesterone, 24
- biomarkers, 18–19
- biotin, 201
- bisphenol-A (BPA), 45
- black cohosh, 191
- block-and-replace therapy, 103, 175
- blood glucose
 balancing, 76
 laboratory assessment of, 65, 66*b*, 114, 148
- botanicals
 adaptogenic, 198
 for hyperthyroidism, 132
 for hypothyroidism, 88
 for thyroid cancer, 166–167
- BPA. *See* bisphenol-A
- bromocriptine, 106, 197
- bugleweed, 132
- bupropion, 25, 26
- cabergoline, 106, 197
- cabozantinib, for thyroid cancer, 142
- calcitriol, 196
- calcium, 88*b*, 121, 125, 192, 196
- calcium carbonate, 192
- calcium citrate, 192
- calorie-controlled diet, 73
- CancerCare, 156
- Caprelsa, for thyroid cancer, 142
- carbohydrates, 122, 197–198
 -controlled diet, 73, 199
 overrestriction, avoiding, 76
- carnitine. *See* L-carnitine
- L-carnitine, 131
- celiac disease, 137, 198, 199
- cellular hypothyroidism, 45
- central hypothyroidism, 48
- CFS. *See* chronic fatigue syndrome
- CH. *See* congenital hypothyroidism
- chasteberry, 192, 197
- chemotherapeutic agents, and hypothyroidism, 45
- chemotherapy, for thyroid cancer, 142
- children, thyroid disease in, 179
 Graves disease, 181–182, 182*b*–183*b*
 hypothyroidism, treatment goals/monitoring, 181
 overt hypothyroidism, 179–180
 subclinical hypothyroidism, 180–181
 thyroid cancer, 184–186, 185*b*
- choriocarcinoma, and hyperthyroidism, 96, 106
- chromium, 25, 76
- chromium picolinate, 88*b*, 193
- chronic fatigue syndrome (CFS), 195–196
- chronic lymphocytic thyroiditis (CLT), 94
- cimetidine, 200
- circadian rhythm, eating according to, 20*b*
- CLA. *See* conjugated linoleic acid

- clinical diagnosis
 hyperthyroid nutrition-related, 119*b*
 hypothyroid nutrition-related, 70*b*
 thyroid nodule/cancer nutrition-related, 153*b*
- CLT. *See* chronic lymphocytic thyroiditis
- coconut oil, 74
- coenzyme Q10 (CoQ10), 167
- coffee, 88*b*
- cognitive behavioral therapy, 195
- cold lasers. *See* low-level laser therapy (LLLT)
- Cometriq, for thyroid cancer, 142
- complementary/alternative medicine use, 194
 hyperthyroidism, 112*b*
 hypothyroidism, 62*b*
 thyroid nodules/thyroid cancer, 146*b*
- compounded thyroid hormones, 54–55, 77
- computed tomography (CT), 185
- congenital hypothyroidism (CH), 37, 44, 179, 181
- conjugated linoleic acid (CLA), 25
- consumptive hypothyroidism, 45
- Contrace, 25
- cool compresses, 195
- coordination of nutrition care, 161
- copper, 74
- CoQ10. *See* coenzyme Q10
- corticosteroids, 197
 for drug-induced thyrotoxicosis, 107
 for Graves ophthalmopathy, 107
- cortisol, 7*b*, 16
 production and function of, 18*t*
 and stress, 22
 weight regulation and relationship to thyroid, 18*t*
- cortisol dysregulation, 20*b*, 197–198, 199
- counseling, nutrition
 hyperthyroidism, 127
 hypothyroidism, 82
 thyroid nodules/cancer, 161
- CT. *See* computed tomography
- curcumin, for hypothyroidism, 87
- Cytomel, 185
 conversion of dosages, 56*t*–57*t*
 for hypothyroidism, 51*t*, 77
- dairy, avoidance of, 77
- D-*chiro*-inositol (DCI), 193
- DCI. *See* D-*chiro*-inositol
- dehydration, 32
- dehydroepiandrosterone (DHEA), 22
- delivery, food/nutrient
 hyperthyroidism, 126–127
 hypothyroidism, 81
 thyroid nodules/cancer, 161
- depression, 193–194
 and weight management, 22–23
- de Quervain thyroiditis, 44, 95
- desiccated thyroid extract medications, 52*t*, 54, 87, 174
- desmopressin, 197
- DEXA. *See* dual energy x-ray absorptiometry
- DHEA. *See* dehydroepiandrosterone
- Diabetes Mellitus Toolkit, 199
- diagnosis, xxiii
 controversy in, 6
 criteria, 4–6, 5*t*
 of hyperthyroidism, 6, 99–100
 of hyperthyroidism in pregnancy, 174
 of hypothyroidism, 6, 48–49
 of hypothyroidism in pregnancy, 172
 nutrition. *See* nutrition diagnosis
 of thyroid nodules/thyroid cancer, 139, 184–185
- diagnostic tests, 175–176
 hyperthyroidism, 115
 hypothyroidism, 66–67
 molecular, 139
 thyroid nodules/thyroid cancer, 149
- diet, 207
 anti-inflammatory diet, 122, 123, 207, 222
 for autoimmune conditions, 199
 autoimmune paleo diet, 199, 223
 calorie-controlled, 73
 carbohydrate-controlled diet, 73, 199
 elimination diet, 24, 122–123
 Fertility Diet, 190
 for fibromyalgia, 195
 gluten-free diet, 190
 high-calorie diet, 122
 high-protein/low-fat diet, 207
 for hyperthyroidism, 126*b*
 and hypothyroidism, 45
 for hypothyroidism, 80*b*
 iodine, 37–38
 iodine-deficient diet, 155
 iron-rich diet, 190
 low-glycemic diet, 19*b*, 20*b*, 220
 low-glycemic/high-fiber diet, 193
 low-iodine diet. *See* low-iodine diet
 low-oxalate diet, 77

- modified texture diet, 79
- optimization, and weight management, 19*b*–20*b*
- for perimenopause and menopause, 191
- for polycystic ovary syndrome, 193
- for thyroid nodules/cancer, 160*b*
- Dietary Reference Intakes (DRIs), 37
 - for estimating fluid requirements, 32*t*
 - vitamin and mineral requirements, 33, 34
- differentiated thyroid cancer (DTC), 137, 176
 - in children, 184
 - treatment goals, 141
- diffuse toxic goiter. *See* Graves disease (GD)
- di-indolemethane (DIM), 191
- diiodothyronine (T2), 3, 19*b*, 36
- DIM. *See* di-indolemethane
- dosage, medication
 - antithyroid drugs, 103
 - hypothyroidism, 55–56, 55*t*, 56*t*–57*t*, 58
 - levothyroxine, 179*t*
 - methimazole, 182*t*
- doxepin, 199
- DRIs. *See* Dietary Reference Intakes
- DTC. *See* differentiated thyroid cancer
- dual energy x-ray absorptiometry (DEXA), 23, 66, 115
- duloxetine, 195
- dysbiosis, and weight management, 25
- eating
 - according to circadian rhythm, 20*b*
 - nighttime, avoiding, 22
- education, nutrition
 - hyperthyroidism, 127
 - hypothyroidism, 82
 - thyroid nodules/cancer, 161
- elderly, thyroid disease in, 178–179
- electrolyte imbalances, 33
- elimination diet, 24, 122–123
- endemic goiter, 37, 45. *See also* goiter
 - food and nutrition-related history, 62*b*–63*b*, 83*b*
 - nutrition monitoring and evaluation, 82, 83*b*–84*b*
- endurance training, 20*b*
- energy balance
 - and hyperthyroid nutrition, 117*b*
 - and hypothyroid nutrition, 68*b*
 - and thyroid nodule/cancer nutrition, 151*b*
- energy, overrestriction of, 76
- energy requirements, 29
 - activity and stress/injury factors, 30*t*
 - calculation of, 29–30
 - indirect calorimetry, 29
 - quick estimation of energy needs, 30, 30*t*
- environmental toxins
 - and hyperthyroidism, 96
 - and hypothyroidism, 45
- Epstein-Barr virus, 46, 97
- essential fatty acids, for hypothyroidism, 87
- estradiol, 24
- estrogen, 18*t*, 24, 190, 191
- eszopiclone, 199
- ETA. *See* European Thyroid Association
- European Thyroid Association (ETA), 54, 170
- euthyroid hyperthyroxinemia, 97
- euthyroidism, definition of, 58
- Euthyrox, for hypothyroidism, 77
- Evidence Analysis Library, 199
- exercise. *See* physical activity
- exophthalmos, 94
- external beam radiation, for thyroid cancer, 142
- familial dysalbuminemic hyperthyroxinemia, 97
- fast foods, 207
- fast thyroid. *See* hyperthyroidism
- fats
 - healthy, 74, 199
 - and weight regulation, 16
- FDA. *See* US Food and Drug Administration
- ferritin, 65, 201
- fertility
 - infertility, 189–190
 - nutrition and lifestyle interventions for, 190
 - thyroid disease screening in, 170–171
- Fertility Diet, 190
- fiber, 191, 192
 - for hyperthyroidism, 126*b*
 - for hypothyroidism, 80*b*, 88*b*
 - rich foods, 74
 - for thyroid nodules/cancer, 161*b*
 - and weight management, 19*b*
- fibromyalgia, 194–195
- finasteride, 200
- fine needle aspiration (FNA) biopsy, 139, 176, 184
- flavonoids, 88*b*

- flaxseed, 191
- fluid intake, 122
 - assessment of, 73
 - for hyperthyroidism, 117*b*, 126*b*
 - for hypothyroidism, 68*b*, 80*b*, 82
 - for thyroid nodules/cancer, 151*b*, 161*b*
- fluid requirements, 31–32
 - estimation, Dietary Reference Intakes, 32*t*
 - fluid volume deficit, 32
- fluoride, for hyperthyroidism, 131
- FNA. *See* fine needle aspiration biopsy
- folate deficiency, 65
- folic acid, 190
- follicular cancer/carcinoma, 138, 185*b*
- food–drug interactions, and hypothyroidism medications, 53
- food intake
 - hyperthyroidism, 111*b*, 126*b*
 - hypothyroidism, 62*b*, 81*b*
 - and levothyroxine absorption, 214
 - thyroid nodules/cancer, 145*b*, 161*b*
 - tracking, 20*b*
- food intake diagnosis
 - hyperthyroid nutrition-related, 117*b*–118*b*
 - hypothyroid nutrition-related, 68*b*–69*b*
 - thyroid nodule/cancer nutrition-related, 151*b*–152*b*
- food sensitivity, and weight management, 24
- free thyroxine (FT4), 6, 7*b*–8*b*, 10*t*, 48, 99, 100, 173, 174, 180
- free triiodothyronine (FT3), 6, 8*b*, 10*t*, 49, 99, 100, 174
- fructose, and weight management, 20*b*
- FT3. *See* free triiodothyronine
- FT4. *See* free thyroxine
- functional domain
 - and hyperthyroid nutrition, 119*b*, 120*b*
 - and hypothyroid nutrition, 70*b*, 72*b*
 - and thyroid nodule/cancer nutrition, 153*b*, 154*b*
- gamma oryzanol, 88*b*
- gastric emptying time, 66
- GD. *See* Graves disease
- genetics
 - and hyperthyroidism, 94
 - and hypothyroidism, 44
 - and thyroid cancer, 137
- germinal mutations, screening for, 139
- gestational hyperthyroidism, 175
- GH. *See* growth hormone
- ghrelin, 15, 16, 20*b*
 - production and function of, 16*t*
 - weight regulation and relationship to thyroid, 16*t*
- Ginkgo biloba*, 132
- glandulars, 52*t*
- glucocorticoids, for Graves ophthalmopathy, 106–107
- glutathione, for hypothyroidism, 87
- gluten, 76, 123
- gluten-free diet, 199, 221
- glyphosate, 19*b*
- GO. *See* Graves ophthalmopathy
- goiter, 36, 45, 58, 122, 193
 - in children, 180
 - medical nutrition therapy for, 79
 - medical treatments, and hypothyroidism, 45
 - nutrition monitoring and evaluation, 82, 83*b*–84*b*
 - nutrition prescription, 80*b*–81*b*
 - toxic multinodular. *See* toxic multinodular goiter (TMNG)
- goitrogens, 37, 45, 76, 79, 82, 103, 131–132, 215
 - and antithyroid drugs, 122
 - and weight management, 19*b*
- Graves dermatopathy, 94–95
- Graves disease (GD), 37, 38, 55, 92, 93, 96, 97, 99, 107*b*–108*b*, 194, 198
 - in children/adolescents, 181–182
 - diagnosis of, 99, 100
 - food and nutrition-related history, 111*b*–112*b*, 128*b*
 - and hyperthyroidism, 94–95
 - and iodide preparations, 123
 - laboratory assessment, 113, 113*t*
 - medical treatments, and hypothyroidism, 45
 - in pediatric patients, treatment concerns, 82*b*–183*b*
 - postpartum, 176
 - in pregnancy, 175, 176
 - treatment for overt hypothyroidism in, 102–106
- Graves ophthalmopathy (GO), 93, 94
 - treatment for hyperthyroidism in, 106–107
- growth hormone (GH), 16, 20*b*
 - low, 24
 - production and function of, 17*t*
 - weight regulation and relationship to thyroid, 17*t*
- gut microbiota, and weight management, 25
- hair loss, 200–201
- Harris-Benedict Equation (HBE), 29–30
- Hashimoto thyroiditis, 43, 45, 46, 49, 58, 87, 123, 198
 - alternatives therapies for, 89
 - diagnosis of, 99
 - diagnostic tests, 66
 - food and nutrition-related history, 62*b*–63*b*, 83*b*
 - and gluten, 76

- and hypothyroidism, 43
- intestinal permeability in, 77, 78*b*
- and iodine, 35, 37, 38
- laboratory assessment, 64, 64*t*
- with lactose intolerance, 77
- medical nutrition therapy for, 77, 78*b*, 79
- nutrition monitoring and evaluation, 82, 83*b*–84*b*
- nutrition prescription, 80*b*–81*b*
- and oxalates, 77
- and thyroid nodules, 137
- and vitamin D deficiency, 75
- hashitoxicosis, 44, 95
- HBE. *See* Harris-Benedict Equation
- HCTZ. *See* hydrochlorothiazide
- health practitioners, advice for, 12–13
- heart palpitations, 201
- Helicobacter pylori*, 97
- hemoglobin values/interpretation for anemia, 65, 65*t*
- herbs, 198, 199
 - for hyperthyroidism, 132
 - for hypothyroidism, 88
 - for thyroid cancer, 166–167
- high-calorie diet, 122
- high-intensity interval training (HIIT), 20*b*
- high-protein/low-fat diet, 207
- HIIT. *See* high-intensity interval training
- history, food and nutrition-related
 - hyperthyroidism, 111*b*–112*b*, 128*b*
 - hypothyroidism, 62*b*–63*b*, 83*b*
 - thyroid nodules/thyroid cancer, 145, 145*b*–147*b*, 163*b*
- hops, 191
- hormone replacement therapy (HRT), 24, 58, 110, 176
- hormones. *See also* thyroid hormones
 - concerns, of women, 189–192
 - involved in weight regulation, 15–16, 16*t*–17*t*
 - laboratory assessment of, 65, 66*b*, 114, 148
- hormone-sensitive lipase (HSL), 15
- HPA. *See* hypothalamic-pituitary-adrenal axis
- HPT. *See* hypothalamic-pituitary-thyroid axis
- HRT. *See* hormone replacement therapy
- HSL. *See* hormone-sensitive lipase
- hunger hormone. *See* ghrelin
- Hürthle cell carcinoma, 138
- hydration, 74, 192
- hydrochlorothiazide (HCTZ), 104–105, 122
- hyperemesis gravidarum, 175
- hyperglycemia, 114
- hypermetabolism, 33
- hyperthyroid eye disease. *See* Graves ophthalmopathy (GO)
- hyperthyroidism, 4, 92
 - biochemical/diagnostic testing frequency, 226–227
 - biological causes of, 94–96
 - complications, 101*b*–102*b*
 - diagnosis, 99–100
 - diagnosis, controversy in, 6
 - etiology of, 93–97
 - and fluid requirements, 31
 - iodine-induced, 36
 - medical treatments, and hypothyroidism, 45
 - nonbiological causes of, 96–97
 - and postpartum period, 176
 - prevention of, 206
 - Recommended Dietary Allowance and Tolerable Upper Intake Level of nutrients for, 33*t*–34*t*
 - risk factors of, 93
 - severity, assessment of, 100–101
 - signs and symptoms of, 92–93, 93*b*
 - subclinical. *See* subclinical hyperthyroidism (SH)
 - and weight gain, 15
- hyperthyroidism, in pregnancy, 174
 - diagnosis and laboratory values, 174
 - monitoring and follow-up, 175–176
 - treatment and monitoring, 175
- hypocalcemia, 196
- hyponatremia, 31
- hypoparathyroidism, 196
- hypothalamic-pituitary-adrenal (HPA) axis, 197
- hypothalamic-pituitary-thyroid (HPT) axis, 2, 3*f*, 197
- hypothalamus, 2, 16, 20*b*, 196
 - disorders, and hypothyroidism, 44–45
- hypothyroidism, 4, 7*b*, 42
 - biochemical/diagnostic testing frequency, 225–226
 - biological causes of, 43–45
 - central, 48
 - in children, 179–181, 186
 - congenital, 37, 44
 - consumptive, 45
 - diagnosis, 48–49
 - diagnosis, controversy in, 6
 - in elderly, 178–179
 - etiology of, 43–46
 - and fluid requirements, 31
 - hypermetabolism in, 33
 - and iodine deficiency, 36, 45, 177, 206
 - medical management. *See* medical management of hypothyroidism
 - nonbiological causes of, 45–46
 - overmedication for, 96–97

- and physical activity, 21
- and postpartum period, 176, 177
- prevention of, 206
- primary, 48, 50
- RDA/AL and UL of nutrients for, 33*t*–34*t*
- risk factors of, 43
- signs and symptoms of, 42*b*–43*b*
- subclinical. *See* subclinical hypothyroidism (SCH)
- untreated/undertreated, complications of, 49*b*
- and weight gain, 15
- hypothyroidism, in pregnancy, 171–172
 - diagnosis and laboratory values, 172
 - medication management, 173
 - monitoring and follow-up, 174
 - treatment goals, 173–174
- hypovolemia, 32
- iatrogenic thyrotoxicosis, 56
- IBS. *See* irritable bowel syndrome
- ice packs, 195
- IgE. *See* immunoglobulin E
- IgG. *See* immunoglobulin G
- IIH. *See* iodine-induced hyperthyroidism
- immunoglobulin E (IgE), 24
- immunoglobulin G (IgG), 24
- incidental activities, 20*b*
- Indian Thyroid Society, 170
- indirect calorimetry, 29
- infants. *See* children, thyroid disease in
- infections
 - and hyperthyroidism, 97
 - and hypothyroidism, 45–46
- infertility, 189–190
- injury, and calculation of energy requirements, 30*t*
- insulin
 - production and function of, 17*t*
 - resistance, and weight management, 23
 - weight regulation and relationship to thyroid, 17*t*
- intelligence quotient (IQ), and iodine, 39, 177
- interferon alpha, and thyrotoxicosis, 107
- interleukin-2, and thyrotoxicosis, 107
- intestinal permeability in Hashimoto thyroiditis, 77, 78*b*
- iodides, 38, 123, 177
- iodine, 36, 74, 79, 82, 88*b*, 156, 207
 - as component to thyroid hormones, 36
 - and dietary concerns, 37–38
 - fetal, 39
 - high-dose, 38
 - and hyperthyroidism, 36–37, 97
 - and hypothyroidism, 36–37
 - inorganic, 100
 - intake, monitoring, 123
 - intake, recommendations, 39*t*
 - level, in thyroid patients, 37*b*
 - low-iodine diet. *See* low-iodine diet
 - and multivitamins, 122
 - and pregnancy/lactation, 177–178, 178*t*
 - radioactive. *See* radioactive iodine (RAI)
 - recommendations, 40
 - supplementation, 38
 - throughout life cycle, 39
 - and thyroid cancer, 206
 - urinary iodine levels, 177, 178*t*
- iodine-123, 176
- iodine-131, 107, 177, 181, 185
- iodine deficiency, xxiii, 36, 38
 - and hypothyroidism, 36, 45, 177, 206
 - and toxic multinodular goiter, 95
- iodine-deficient diet, 155
- iodine-induced hyperthyroidism (IIH), 36, 96, 206
- ipsilateral thyroid lobectomy, 105
- IQ. *See* intelligence quotient, and iodine
- iron, 75, 88*b*, 195, 201
- iron-deficiency anemia, 65
- iron-rich diet, 190
- irritable bowel syndrome (IBS), 79
- isoflavones, 38, 76
- knowledge/beliefs/attitudes
 - hyperthyroidism, 112*b*, 120*b*
 - hypothyroidism, 62*b*–63*b*, 71*b*
 - thyroid nodule/cancer, 146*b*, 154*b*
- kombu, 132
- laboratory assessment
 - of anemias, 65, 65*t*
 - of hormones, lipids and blood glucose, 65, 66*b*, 114, 148
 - hyperthyroidism in pregnancy, 174
 - hypothyroidism in pregnancy, 172
 - of micronutrients, 65, 66*b*, 114*b*–115*b*, 148, 149*b*
 - of thyroid hormones, 6, 7*b*–9*b*, 10*t*, 64, 64*t*, 113, 113*t*, 147–148
- lactation
 - and iodine, 38, 177–178, 178*t*
 - and thyroid disease, 176–178

- lactic acid bacteria, 196
- lactose intolerance, Hashimoto thyroiditis with, 77
- LBM. *See* lean body mass
- LC-MS/MS. *See* liquid chromatography–tandem mass spectrometry assays
- LDN. *See* low-dose naltrexone, for hypothyroidism
- lean body mass (LBM), 23
- lemon balm, 132
- leptin, 15, 16
 - production and function of, 16*t*
 - and stress, 22
 - weight regulation and relationship to thyroid, 16*t*
- levodopa, and tyrosine, 74
- Levo-T, for hypothyroidism, 50*t*
- levothyroxine (L-T4), 4, 6*b*, 15, 36, 77, 106, 147–148, 162, 171, 175
 - absorption, 53, 214
 - brand-name vs generic, 52–53
 - food–drug interactions, 53
 - for hypothyroidism, 50, 50*t*, 52–54
 - monitoring, 58–59
 - needs based on age, 179*t*
 - and postpartum period, 176
 - and pregnancy, 173, 174
 - timing of medication, 53
 - use in children, 179, 180, 181
 - use in elderly, 179
 - and weight management, 19*b*
- levothyroxine sodium, for hypothyroidism, 50*t*
- Levoxyl, for hypothyroidism, 50*t*, 77
- lid-lag, 93
- lifestyle practices
 - autoimmune diseases, 198–199
 - chronic fatigue syndrome, 196
 - cortisol dysregulation, 197–198
 - depression and mood disorders, 194
 - fertility, 190
 - fibromyalgia, 195
 - hair loss, 200–201
 - hyperthyroidism, 125
 - hypothyroidism, 79
 - parathyroid disease, 196
 - perimenopause and menopause, 190–192
 - polycystic ovary syndrome, 193
 - premenstrual syndrome, 192
 - prevention of thyroid disease, 207*b*–208*b*
 - sleep difficulties, 200
 - thyroid cancer, 160, 206
- life-threatening thyrotoxicosis. *See* thyroid storm
- liothyronine (L-T3), 180, 193
 - for hypothyroidism, 50, 51*t*, 54
 - and weight management, 19*b*
- lipids, laboratory assessment of, 65, 66*b*, 114, 148
- lipoprotein lipase (LPL), 15
- liquid chromatography–tandem mass spectrometry (LC-MS/MS) assays, 173
- lithium, 193
- liver function tests, 114
- LLLT. *See* low-level laser therapy
- lorcaserin HCl, 25
- low-dose naltrexone (LDN), for hypothyroidism, 58, 87
- low-glycemic diet, 19*b*, 20*b*, 220
- low glycemic/high-fiber diet, 193
- low-iodine diet, 39, 141, 156, 157*b*, 216–219
 - beverages, 218
 - bread and cereals, 216
 - desserts and sweets, 218
 - fat, 217
 - fruits and vegetables, 217
 - meat and meat substitutes, 216
 - milk and milk products, 217
- low-level laser therapy (LLLT), 58
- low-oxalate diet, 77
- LPL. *See* lipoprotein lipase
- L-T3. *See* liothyronine
- L-T4. *See* levothyroxine
- maca, 191
- macronutrients, 73
- magnesium, 25, 76, 132, 191, 192
- magnolia, for hypothyroidism, 87
- males, with low testosterone, 24
- maternal hypothyroidism, 174
- MCTs. *See* medium-chain triglycerides
- meal replacements, and weight management, 20*b*
- medical food supplements, 81
- medical/health history
 - hyperthyroidism, 116, 128*b*
 - hypothyroidism, 67, 84*b*
 - thyroid nodules/thyroid cancer, 150, 164*b*
- medical management of hyperthyroidism, 99
 - drug-induced thyrotoxicosis, 107
 - goals, 107
 - Graves ophthalmopathy, 106–107
 - medications, 103–104, 104*b*

- monitoring, 107*b*–108*b*
- radioactive iodine, 104–105
- subclinical hyperthyroidism, 102
- surgery, 105–106
- thyroid-stimulating hormone-secreting pituitary adenoma, 106
- treatment options, 100
- medical management of hypothyroidism, 48, 50
 - absorption, 53
 - brand-name vs generic levothyroxine, 52–53
 - combining medications, 54
 - compounded thyroid hormones, 54–55, 77
 - conversion of dosages, 56*t*–57*t*, 58
 - dosage, 55, 55*t*
 - extreme dosages, avoiding, 56
 - food–drug interactions, 53
 - goals, 58
 - medication options, 50*t*–52*t*
 - monitoring, 58–59
 - specialist, referral to, 59
 - timing of medications, 53
 - TSH levels, monitoring, 59
- medical management of thyroid cancer, 139
 - benign nodules, treatment goals, 141
 - malignant nodules, treatment goals, 141–142
 - monitoring, 142–143
- medical nutrition therapy (MNT)
 - for goiter, 79
 - for Hashimoto thyroiditis, 77, 78*b*, 79
 - for hyperthyroidism, 121–123
 - for hypothyroidism, 72–77
 - for thyroid cancer, 155
- medications
 - for hair loss, 200
 - and hyperthyroidism, 112*b*
 - and hypothyroidism, 45, 62*b*
 - for hypothyroidism, in pregnancy, 173
 - interfering levothyroxine absorption, 214
 - sleep, 199–200
 - that affect thyroid-stimulating hormone, 214
 - thyroid. *See* thyroid medications
 - and thyroid nodules, 146*b*
 - weight loss, 25–26
- meditation, 197
- medium-chain triglycerides (MCTs), 74
- medroxyprogesterone, 24
- medullary thyroid cancer/carcinoma (MTC), 138, 176, 185*b*
- melatonin, 24, 166, 200
- Memorial Sloan Kettering Cancer Center, 166
- menopause
 - nutrition/lifestyle interventions for, 190–192
 - and weight management, 24
- menstrual abnormalities, 189–190
- mercury, and hyperthyroidism, 96
- metformin, 26, 192
- methimazole (MMI)
 - for drug-induced thyrotoxicosis, 107
 - for hyperthyroidism, 103, 104*b*, 105, 106, 108*b*, 175, 176
 - use in children, 181, 182*t*
- methylcobalamin, 76
- MI. *See* *myo*-inositol
- micronutrients, laboratory assessment of, 65, 66*b*, 114*b*–115*b*, 148, 149*b*
- Mifflin-St Jeor equation, 29
- milnacipran, 195
- minerals
 - for hyperthyroidism, 126*b*
 - for hypothyroidism, 81*b*
 - repletion of, 124–125
 - requirements, 33, 35
 - supplements, 81
 - for thyroid nodules/cancer, 161*b*
- minoxidil, 200
- mitochondria, 16
- MMI. *See* methimazole
- MNT. *See* medical nutrition therapy
- modified texture diet, 79
- molecular diagnostic tests, 139
- monodeiodination, 3, 36
- monoiodothyronine (T1), 3, 36
- mood disorders, 193–194
- MS. *See* multiple sclerosis
- MTC. *See* medullary thyroid cancer/carcinoma
- multiminerals, 81, 122
- multiple sclerosis (MS), 198
- multivitamins, 74, 88*b*, 122
- myo*-inositol (MI), 193
- n-3 fatty acids, 74, 193, 194, 195, 199
- n-3 fish oil, 25
- n-6 fatty acids, 195
- NAC. *See* N-acetylcysteine
- N-acetylcysteine (NAC), 193

- naltrexone, 25, 79
for hypothyroidism, 58, 87
- National Center for Complementary and Integrative Health, 195
- National Institutes of Health (NIH), 39, 156, 195
- Natural Medicines Comprehensive Database, 88, 195
- Natural Medicines Database, 74
- Nature-Throid
conversion of dosages, 56*t*–57*t*
for hypothyroidism, 52*t*, 77
- NCP. *See* Nutrition Care Process
- near-total thyroidectomy, 105, 143
- neck, self-check of, 224
- Nexavar, for thyroid cancer, 142
- NIH. *See* National Institutes of Health
- nodules. *See* thyroid nodules
- nonbioidentical progesterone, 24
- Novothyrox, for hypothyroidism, 50*t*
- nuclear power plants, 45, 137, 206
- nuclear scan, 100
- nutrient deficiencies, and weight management, 25
- nutrient intake
hyperthyroidism, 111*b*, 118*b*
hypothyroidism, 62*b*, 69*b*
thyroid nodules/cancer, 145*b*, 151*b*–152*b*
- nutritional status/outcomes
in adult hyperthyroid patients, 129
in hypothyroid patients, 84
in thyroid cancer patients, 164
- nutrition assessment for hyperthyroidism, 111
anthropometric assessment, 113, 128*b*
biochemical data, medical tests, and procedures, 113–115, 128*b*
client history, 116, 128*b*
food and nutrition-related history, 111*b*–112*b*, 128*b*
physical findings, 115, 128*b*
- nutrition assessment for hypothyroidism, 62
anthropometric assessment, 63–64, 83*b*
biochemical data, medical tests, and procedures, 64–67, 83*b*
food and nutrition-related history, 62*b*–63*b*, 83*b*
physical findings, 67, 83*b*
- nutrition assessment for nodules/thyroid cancer, 145
anthropometric assessment, 147, 163*b*
biochemical data, medical tests, and procedures, 147–150, 163*b*
client history, 149*b*, 150, 164*b*
food and nutrition-related history, 145*b*–147*b*, 163*b*
physical findings, 149–150, 163*b*–164*b*
- nutrition care, 10–12
- Nutrition Care Process (NCP), 11*b*, 12, 68, 81, 111, 145, 161
- nutrition diagnosis
hyperthyroidism, 116, 117*b*–120*b*
hypothyroidism, 68, 68*b*–72*b*
thyroid cancer, 150–151, 151*b*–154*b*
- nutrition intervention for hyperthyroidism, 120–121
lifestyle and behavior changes, 125
medical nutrition therapy, 121–123
planning, 121
repletion of vitamin and mineral deficits, 124
steps and goals, 121, 121*b*
strategies, 126–127
- nutrition intervention for hypothyroidism, 72
goiter, 79
Hashimoto thyroiditis, 77, 78*b*, 79
lifestyle and behavior changes, 79
medical nutrition therapy, 72–77
planning, 72
steps and goals, 72, 73*b*
strategies, 81–82
- nutrition intervention for thyroid nodules/cancer, 155
complications of radioactive iodine, 158*b*–159*b*
lifestyle and behavior changes, 160
medical nutrition therapy, 155
radioactive iodine and low-iodine diet, 156, 157*b*
steps and goals, 155–156
strategies, 161–162
- nutrition monitoring and evaluation
hyperthyroidism, 127, 128*b*, 129
hypothyroidism, 82, 83*b*–84*b*
thyroid cancer, 163*b*–164*b*
- nutrition objectives
hyperthyroidism, 110–111
hypothyroidism, 61
thyroid cancer, 144–145
- nutrition prescription
hyperthyroidism, 125, 126*b*
hypothyroidism, 79, 80*b*–81*b*
thyroid nodules/cancer, 160*b*–161*b*
- obesity, and thyroid cancer, 137
- octreotide, 197
- OH. *See* overt hypothyroidism
- oral/nutrition support intake
and hyperthyroid nutrition, 117*b*
and hypothyroid nutrition, 68*b*
and thyroid nodule/cancer nutrition, 151*b*

- Ord disease, and hypothyroidism, 44
- orlistat, 25, 192–193
- ovarian teratoma. *See* struma ovarii
- overhydration, 32
- overt hyperthyroidism, 92
 - diagnosis of, 99
 - signs and symptoms of, 92
 - treatment for, 102–106
- overt hypothyroidism (OH), 21, 189, 193
 - in children, 179–180
 - and fertility, 170, 171
 - in pregnancy, 170, 171–172, 173, 174
- oxalates, 77
- Oxalobacter formigenes*, 77
- oxalyl-CoA decarboxylase, 77
- Panax ginseng*, 192
- pantothenic acid. *See* vitamin B5
- papillary cancer/carcinoma, 137, 185*b*
- parathyroid disease, 196
- parathyroid hormone (PTH), 196
- patient/client-centered measures, nutrition-related
 - hyperthyroidism, 112*b*
 - hypothyroidism, 63*b*
 - thyroid nodules/thyroid cancer, 147*b*
- PCOS. *See* polycystic ovary syndrome
- perimenopause, nutrition/lifestyle interventions for, 190–192
- personal history
 - hyperthyroidism, 116, 128*b*
 - hypothyroidism, 67, 84*b*
 - thyroid nodules/thyroid cancer, 150, 164*b*
- PES (Problem, Etiology, and Signs and Symptoms)
 - statements
 - hypothyroid nutrition-related diagnosis, 68*b*–72*b*
- pesticides, 19*b*
- phentermine, 25
- phosphatidylserine, 87, 198, 200
- phosphorus, 121
- physical activity, 191, 192, 196, 197, 207
 - and calculation of energy requirements, 30*t*
 - and hyperthyroidism, 112*b*, 120*b*
 - for hyperthyroidism, 125
 - and hypothyroidism, 63*b*, 72*b*
 - for hypothyroidism, 79
 - for polycystic ovary syndrome, 193
 - and thyroid, evidence regarding, 21
 - and thyroid nodule/cancer, 146*b*–147*b*, 154*b*
 - for weight loss and prevention of weight regain, 21*b*
 - and weight management, 20*b*
- physical findings, nutrition-focused
 - hyperthyroidism, 115, 128*b*
 - hypothyroidism, 67, 83*b*
 - thyroid nodules/thyroid cancer, 149–150, 163*b*–164*b*
- pituitary gland, 2
 - disorders, and hypothyroidism, 44–45
 - problems, 196–197
 - thyroid-stimulating hormone-secreting pituitary
 - adenoma, 96, 100
- plasmapheresis, 105
- Plummer disease. *See* toxic adenoma (TA)
- PMS. *See* premenstrual syndrome
- polycystic ovary syndrome (PCOS), 23, 189, 192–193
- postpartum period, and thyroid disease, 176–178
- postpartum thyroiditis, 176, 177, 193
 - and hyperthyroidism, 95
 - and hypothyroidism, 44
- potassium, 122
- potassium iodide, 105, 137, 206
- prednisone, 26
- pregabalin, 195
- pregnancy
 - and iodine, 38, 177–178, 178*t*
 - prevention of thyroid disease in, 206
 - and radioactive iodine ablation, 105
 - thyroid disease screening in, 170–171
- premenstrual syndrome (PMS), 192
- prenatal patients, thyroid disease in, 171
 - hyperthyroidism, 174–176
 - hypothyroidism, 171–174
 - thyroid nodules/cancer, 176
- pretibial myxedema. *See* Graves dermopathy
- prevention of thyroid disease, 205
 - food and lifestyle practices, 207*b*–208*b*
 - hyperthyroidism, 206
 - hypothyroidism, 206
 - in pregnancy, 206
 - primary, 205
 - secondary, 205
 - tertiary, 205
 - thyroid cancer, 205–206
- primary hyperparathyroidism, 196
- primary hypothyroidism, 48, 50
- probiotics, 87, 197
- progesterone, 18*t*, 24, 190

- propylthiouracil (PTU), for hyperthyroidism, 103, 104*b*, 175, 176
- protein, 77, 122, 193, 197
intake, and weight management, 16, 20*b*
plant-based, 199
requirements, 31, 31*t*
- proteolytic enzymes. *See* systemic enzymes
- PTH. *See* parathyroid hormone
- PTU. *See* propylthiouracil, for hyperthyroidism
- pyridoxine. *See* vitamin B6
- Qsymia, 25
- quercetin, 166, 195
- radioactive iodine (RAI), 122, 206
complications and nutritional strategies, 158*b*–159*b*
for hyperthyroidism, 37, 39, 55, 100, 104–105
and pregnancy, 176
for thyroid cancer, 141–142, 150, 156, 157, 160
use in children/pediatric patients, 183*b*–184*b*, 184, 185
- radionuclide scanning, 139
- RAI. *See* radioactive iodine
- ramelteon, 199
- RDA. *See* Recommended Dietary Allowance
- RDNs. *See* registered dietitian nutritionists
- Recommended Dietary Allowance (RDA), 33*t*–34*t*, 37
- red ginseng, 192
- registered dietitian nutritionists (RDNs), 10
- resistance training, 20*b*
- resting energy metabolism, 23
- resting metabolic rate (RMR), 23, 29, 66, 79
- restorative yoga, 20*b*
- resveratrol, 166, 191
- reverse T3 (RT3), 3, 7*b*, 8*b*–9*b*, 10*t*, 18–19, 36, 49
- rheumatoid arthritis, and physical activity, 21
- Riedel thyroiditis, 44, 95
- RMR. *See* resting metabolic rate
- Royal College of Physicians of London, 48
- RT3. *See* reverse T3
- salivary cortisol tests, 197
- saturated fats, and weight management, 20*b*
- Saxenda (liraglutide) injection, 25
- SCH. *See* subclinical hypothyroidism
- seaweed, 132
- secondary hyperparathyroidism, 196
- selenium, 74–75, 79, 94, 123, 174
- serotonin, and stress, 22
- serum thyroxine. *See* total thyroxine (TT4)
- serum triiodothyronine. *See* total triiodothyronine (TT3)
- sex hormones, 197
production and function of, 18*t*
weight regulation and relationship to thyroid, 18*t*
- SH. *See* subclinical hyperthyroidism
- Siberian rhubarb, 191
- silent thyroiditis, 95
- Sjögren syndrome, 198
- sleep, 199
difficulties, 199–200
and weight management, 22
- slow thyroid. *See* hypothyroidism
- smoking, and Graves ophthalmopathy, 106, 116
- social history
hyperthyroidism, 116, 128*b*
hypothyroidism, 67, 84*b*
thyroid nodules/thyroid cancer, 150, 164*b*
- sodium, 77, 192
- sorafenib, for thyroid cancer, 142
- soy consumption, 76
and thyroid cancer, 155
and thyroid medication, 19
- soy isoflavones, 38, 76
- Spanish Society of Endocrinology and Nutrition, 170
- specialists, referral to, 59, 79, 125, 162
- spices, 199
- spironolactone, 200
- steady-state exercise, 20*b*
- St John's wort, 192, 194
- stomach acid, and weight management, 25
- strength training, 20*b*, 21, 79, 191
- stress
and calculation of energy requirements, 30*t*
and hyperthyroidism, 96
and hypothyroidism, 45
management, 195
and weight management, 22
- struma ovarii, and hyperthyroidism, 96, 106
- subclinical hyperthyroidism (SH), 92
diagnosis of, 100
signs and symptoms of, 92

- treatment of, 102
- subclinical hypothyroidism (SCH), 5, 42, 50, 193, 198
 - children with, 180–181
 - in elderly, 179
 - and fertility, 170, 171
 - in pregnancy, 170, 171, 172, 173, 174
- subclinical thyrotoxicosis, 102
- sugar, and weight regulation, 16
- supplements, 207
 - for estrogen dominance, 191
 - for hair loss, 201
 - for hyperthyroidism, 132
 - for hypothyroidism, 88, 88*b*
 - interfering levothyroxine absorption, 214
 - iodine, 38
 - medical food, 81
 - multivitamin-mineral, 122
 - for polycystic ovary syndrome, 193
 - for premenstrual syndrome, 192
 - for thyroid cancer, 166–167
 - and thyroid medication, 19, 53
 - vitamin/mineral, 81, 124–125
 - and weight management, 25
- surgery. *See also* thyroidectomy
 - in children, 181, 186
 - for goiter, 122
 - for hyperthyroidism, 105–106
 - for thyroid cancer, 141, 176
- swallowing, palliative care for, 122
- Synthroid
 - conversion of dosages, 56*t*–57*t*
 - for hypothyroidism, 50*t*, 77
- systemic enzymes, for Hashimoto thyroiditis, 89
- T1. *See* monoiodothyronine
- T2. *See* diiodothyronine
- T3. *See* triiodothyronine
- T3 resin uptake, 8*b*
- T3/T4 combination therapy
 - for hypothyroidism, 51*t*–52*t*, 54
 - and pregnancy, 174
- T3 toxicosis, 100
- T4. *See* thyroxine
- TA. *See* toxic adenoma
- TAb. *See* thyroid antibody
- tai chi, 195
- Tapazole, for hyperthyroidism, 103, 104*b*
- targeted drug therapies, for thyroid cancer, 142
- TBG. *See* thyroid-binding globulin; thyroxine-binding globulin
- technetium, 176
- TEE. *See* total energy expenditure
- testosterone, 18*t*
 - males with low testosterone, 24
- Tg. *See* thyroglobulin
- TgAb. *See* thyroglobulin antibody
- L-theanine, 132
 - for hypothyroidism, 87
- thiamine. *See* vitamin B1
- thioamides, 38
- thionamides. *See* antithyroid drugs (ATDs)
- Thyroflex test, 66
- Thyrogen, 142, 162
- thyroglobulin (Tg), 8*b*, 143, 148, 176
- thyroglobulin antibody (TgAb), 9*b*, 10*t*, 49, 73, 94, 99, 148
- thyroid, 2
 - anatomy, 2*f*
- thyroid antibody (TAb), 170
- thyroid-binding globulin (TBG), 6
- thyroid cancer, 19*b*, 38–39
 - access to food and food- or nutrition-related supplies, 146*b*
 - biochemical/diagnostic testing frequency, 228
 - in children, 184–186, 185*b*
 - diagnosis of, 139, 184–185
 - medical treatments, and hypothyroidism, 45
 - monitoring of, 143
 - in pregnancy, 176
 - prevalence and incidence of, 136
 - prevention of, 205–206
 - prognosis and staging, 140
 - risk, and physical activity, 21
 - risk factors of, 137
 - risk stratification of death from, 140
 - severity, assessment of, 140
 - signs and symptoms of, 136
 - types of, 137–138
- Thyroid Cancer Survivor Association, 156
- thyroid collar, 206
- thyroid disorders, 4
 - diagnostic criteria, 4–6
 - and health impact, 4
- thyroidectomy, 99, 105, 106, 122, 141, 147–148, 175, 181, 184*b*, 196
- thyroid function tests, 18, 52
- thyroid hormones, xxiii, 2, 3, 3*f*, 197
 - dysfunction, xxiii

- iodine as component to, 36
- and iodine intake, 123
- laboratory measures of, 6, 7*b*–9*b*, 10*t*, 64, 64*t*, 113, 113*t*, 147–148
- levels, 7*b*
- thyroiditis, 122
 - autoimmune thyroiditis, 94
 - chronic lymphocytic thyroiditis, 94
 - Hashimoto thyroiditis. *See* Hashimoto thyroiditis
 - and hyperthyroidism, 95
 - and hypothyroidism, 44
 - postpartum. *See* postpartum thyroiditis
- thyroid lymphoma, 138
- thyroid medications. *See also* medical management of
 - hyperthyroidism; medical management of
 - hypothyroidism; medical management of thyroid cancer
- dosage, 55*t*
- food interactions with, 19, 53
- iodine in, 36
- peripheral metabolism, factors that affect, 214
- supplement interactions with, 19, 53
- and weight management, 19*b*
- thyroid nodules, xxiii, 136
 - benign, treatment goals, 141
 - biochemical/diagnostic testing frequency, 227
 - in children, 184
 - diagnosis of, 139, 184–185
 - and hyperthyroidism, 95–96
 - malignant, treatment goals, 141–142
 - medical treatments, and hypothyroidism, 45
 - monitoring of, 142
 - in pregnancy, 176
 - prevalence and incidence of, 136
 - risk factors of, 137
 - signs and symptoms of, 136
- thyroid peroxidase (TPO), 49, 75
- thyroid peroxidase antibody (TPOAb), 8*b*, 10*t*, 73, 94, 189
- thyroid sarcoma, 138
- thyroid-stimulating hormone (TSH), 2, 4, 10*t*, 18–19, 48, 99, 106, 139, 148, 170, 171, 174
 - for assessing thyroid status, concerns, 5
 - and diagnostic criteria, 4–5
 - guidelines, trimester-specific, 172*t*
 - and hypothyroidism in pregnancy, 172
 - levels, challenges to treatment based on, 6*b*
 - levels, interpretation and expected hormonal profile, 5*t*
 - monitoring, while taking medications, 59
 - nutrition-related medications that affect, 214
 - screening, conditions that warrant, 48*b*
 - suppressive therapy, 148
 - and thyroid medications, 53
- thyroid stimulating hormone receptor antibody (TRAb), 9*b*, 94, 174, 175
- thyroid-stimulating hormone-secreting pituitary adenoma and hyperthyroidism, 96, 100
 - treatment for, 106
- thyroid-stimulating immunoglobulin (TSI), 99
 - antibodies, 9*b*, 10*t*, 94
- thyroid storm, 38, 93, 100
 - medical treatment for, 100
- Thyrolar
 - conversion of dosages, 56*t*–57*t*
 - for hypothyroidism, 51*t*
- Thyro-Tab, for hypothyroidism, 50*t*
- thyrotoxic crisis. *See* thyroid storm
- thyrotoxicosis, 38, 44, 92
 - drug-induced, treatment for, 107
 - iatrogenic, 56
 - presentation, assessment of, 100
 - transient, 95
- thyrotoxicosis factitia, and hyperthyroidism, 96–97
- thyrotropin. *See* thyroid-stimulating hormone (TSH)
- thyrotropin-releasing hormone (TRH), 2
- thyroxine (T4), 3, 6*b*, 7*b*, 36
- thyroxine-binding globulin (TBG), 9*b*, 97
- L-thyroxine. *See* levothyroxine (L-T4)
- timing of hypothyroidism medications, 53
- Tirosint
 - conversion of dosages, 56*t*–57*t*
 - for hypothyroidism, 50*t*, 53, 77
- tissue hypothyroidism, 45
- TMNG. *See* toxic multinodular goiter
- Tolerable Upper Intake Level (UL), 33*t*–34*t*
- total energy expenditure (TEE), 30
- total thyroidectomy, 15, 105, 143, 147–148
- total thyroxine (TT4), 6, 7*b*, 99, 173, 174, 180
- total triiodothyronine (TT3), 6, 8*b*, 19*b*, 49, 54, 99, 174
- toxic adenoma (TA)
 - and hyperthyroidism, 93–94, 95–96
 - treatment for overt hypothyroidism in, 102–106, 108*b*
- toxic multinodular goiter (TMNG)
 - and hyperthyroidism, 93, 95, 97
 - treatment for overt hypothyroidism in, 102–106, 108*b*
- toxins
 - and hyperthyroidism, 96
 - and hypothyroidism, 45
 - and weight management, 24–25
- TPO. *See* thyroid peroxidase

- TPOAb. *See* thyroid peroxidase antibody
- TRAb. *See* thyroid stimulating hormone receptor antibody
- transient thyrotoxicosis, 95
- transthyretin (TTR), 97
- trazodone, 199
- TRH. *See* thyrotropin-releasing hormone
- triiodothyronine (T3), 3, 6*b*, 7*b*, 36, 49, 194
 production and function of, 17*t*
 weight regulation and relationship to thyroid, 17*t*
- Triostat, for hypothyroidism, 51*t*
- Tritostat, for hypothyroidism, 51*t*
- TSH. *See* thyroid-stimulating hormone
- TSI. *See* thyroid-stimulating immunoglobulin
- TT3. *See* total triiodothyronine
- TT4. *See* total thyroxine
- TTR. *See* transthyretin
- turmeric, 79, 191
- Turner syndrome, 43
- type 1 diabetes, 198, 199
- tyrosine, dietary, 74
- UBW. *See* usual body weight
- UICC. *See* Union for International Cancer Control
- UL. *See* Tolerable Upper Intake Level
- ultrasound, 66, 100, 115, 136, 139, 176
- underactive thyroid. *See* hypothyroidism
- undertreatment of thyroid disease, 45, 49*b*, 201
- undifferentiated carcinoma, 138
- Union for International Cancer Control (UICC), 140
- Unithroid, for hypothyroidism, 50*t*
- urinary iodine levels, 177–178, 178*t*
- urinary oxalate test, 77
- US Food and Drug Administration (FDA), 25, 52, 54, 66, 77, 195
- US Preventive Services Task Force, 48
- usual body weight (UBW), 64, 147
- Valerian root extract, 192
- vanadium, 25
- vandetanib, for thyroid cancer, 142
- vegetables, 199
- vitamin A, 75, 76, 121, 167
- vitamin B1, 124
- vitamin B2, 76
- vitamin B5, 124
- vitamin B6, 76, 124
- vitamin B12, 76, 121–122, 124
- vitamin B12 deficiency anemia, 65
- vitamin C, 121, 124, 201
- vitamin D, 25, 75–76, 94, 121, 124, 195, 196
 deficiency, and hyperthyroidism, 124
 deficiency, and hypothyroidism, 45, 75
- vitamin E, 76, 125, 167, 191
- vitamin K2, 76
- vitamins, 33, 35
 for hyperthyroidism, 126*b*
 for hypothyroidism, 81*b*
 repletion of, 124–125
 supplements, 81
 for thyroid nodules/cancer, 161*b*
- walking, 79
- weight, 190
 and hyperthyroidism, 100, 119*b*
 and hypothyroid nutrition, 70*b*
 regain of, 122
 and thyroid nodule/cancer nutrition, 153*b*
- weight regulation, 15
 additional testing, 32
 antioxidant and nutrient deficiencies, 25
 behavioral strategies, 22–23
 diet optimization, 19*b*–20*b*
 food sensitivity, 24
 gut microbiota, 25
 hormones involved in, 15–16, 16*t*–17*t*
 and insulin resistance, 23
 low growth hormone, 24
 low stomach acid and dysbiosis, 25
 males with low testosterone, 24
 menopause, 24
 physical activity and thyroid, evidence regarding, 21
 physical activity for weight loss and prevention of
 weight regain, 21*b*
 physical activity optimization, 20*b*
 polycystic ovary syndrome, 23
 realistic goals, setting, 26
 supplements, 25
 and thyroid medications, 19*b*
 toxins, 24–25
 weight loss techniques, thyroid-specific, 18–19
- whole body iodine scan, 143
- Wobenzym, 89

Wolff-Chaikoff effect, 38, 123

WPthyroid, for hypothyroidism, 52*t*, 77

xerostomia, 122

Yersinia enterocolitica, 45, 97

yoga, 79, 193

restorative, 20*b*

zaleplon, 199

zinc, 25, 74, 125, 196

zolpidem, 199

SAMPLE Print
Not for Resale

Errata

The Health Professional's Guide to Nutrition Management of Thyroid Disease

A corrupt file caused several symbol replacement errors in section 1.

Page and location	Original	Corrected
4, Understanding Diagnostic Criteria	The statement noted that in the future, it is likely that the “limit of the serum TSH euthyroid reference range will be reduced to 2.5 mIU/L because less than 95% of rigorously screened normal euthyroid volunteers have serum TSH values between 0.4 and 2.5 mIU/L. ... A serum TSH result between 0.5 and 2.0 mIU/L is generally considered the therapeutic target for a standard levothyroxine (L-T4) replacement dose for primary hypothyroidism.” ¹⁰	The statement noted that in the future, it is likely that the “limit of the serum TSH euthyroid reference range will be reduced to 2.5 mIU/L because more than 95% of rigorously screened normal euthyroid volunteers have serum TSH values between 0.4 and 2.5 mIU/L. ... A serum TSH result between 0.5 and 2.0 mIU/L is generally considered the therapeutic target for a standard levothyroxine (L-T4) replacement dose for primary hypothyroidism.” ¹⁰
7, Box 1.3	Free Thyroxine, Free T4 (FT4) The amount of unbound T4 in the blood; >1% of T4 is unattached. Free thyroxine affects tissue function in the body. Most tests are affected by the carrier protein concentration in the serum.	Free Thyroxine, Free T4 (FT4) The amount of unbound T4 in the blood; <1% of T4 is unattached. Free thyroxine affects tissue function in the body. Most tests are affected by the carrier protein concentration in the serum.
7, Box 1.3	Free Triiodothyronine, Free T3 (FT3) The amount of free, unbound T3 in the blood; >1% of T3 is unattached. T3 has a greater effect on the body's utilization of energy than T4.	Free Triiodothyronine, Free T3 (FT3) The amount of free, unbound T3 in the blood; <1% of T3 is unattached. T3 has a greater effect on the body's utilization of energy than T4.

Page 18 ■ Under the heading Thyroid-Specific Weight Loss Techniques, in the list of biomarkers commonly tested, number 2 should read **Thyroxine** (T4) (free or total).

Page 115 ■ In Box 11.2, the first sentence in the box should read as follows: Thyroid antibodies (positive thyroid stimulating immunoglobulin [TSI] indicating Graves disease or, if thyroid peroxidase [TPO] but not TSI or **thyroid-stimulating hormone receptor antibodies** [TRAbs], Hashimoto thyroiditis).

Page 140 ■ The title of Box 14.1 should be Risk Stratification of **Recurrence of** Thyroid Cancer.

Please contact publications@eatright.org with any questions or concerns.

eat
right. Academy of
Nutrition
and Dietetics

120 S. Riverside Plaza, Suite 2190
Chicago, IL 60606-6995
www.eatright.org

September 2020